[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 179
1. Hagiwara M, Takata K, Shimoyama Y, Yamamoto K, Takahashi E, Asano N, Iwase Y, Okazaki Y, Tamada Y, Yoshino T, Tomita Y, Nakamura S: Primary cutaneous T-cell lymphoma of unspecified type with cytotoxic phenotype: clinicopathological analysis of 27 patients. Cancer Sci; 2009 Jan;100(1):33-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous T-cell lymphoma of unspecified type with cytotoxic phenotype: clinicopathological analysis of 27 patients.
  • The objective of our study was to investigate the clinicopathological features of the currently ill-defined subtype of primary cutaneous T-cell lymphoma of unspecified type (CTCLU) with a cytotoxic phenotype and no Epstein-Barr virus (EBV) association.
  • The International Prognostic Index was high or high to intermediate in 11%, and the Prognostic Index for Peripheral T-cell Lymphoma unspecified was above group 2 in 22%.
  • Notably, the rates of spontaneous regression and T-cell receptor gene rearrangements by polymerase chain reaction analysis were seen in 26 and 17% of our cases, respectively.
  • (1) epidermotropic CD8+ T-cell lymphoma (n=5);.
  • (2) cutaneous gamma/delta T-cell lymphoma (n=8);.
  • (3) cutaneous alpha/beta pleomorphic T-cell lymphoma (n=8); and (4) cutaneous medium/large pleomorphic T-cell lymphoma, not otherwise specified (n=6).
  • However, epidermotropic CD8+ T-cell lymphoma appeared to be unique with a higher ratio (80%) of spontaneous regression, a lower ratio (40%) of subcutaneous involvement, and a more favorable clinical course than the other three subcategories.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018763.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Choi W, Park YH, Paik KH, Chang YH, Lee SS, Ryoo BY, Yang SH: Peripheral T-cell lymphoma-unspecified (PTCL-U) presenting with hypereosinophilic syndrome and pleural effusions. Korean J Intern Med; 2006 Mar;21(1):57-61
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma-unspecified (PTCL-U) presenting with hypereosinophilic syndrome and pleural effusions.
  • Hypereosinophilic syndrome (HES) is a clinical disorder characterized by persistent eosinophilia and systemic involvement, in which a specific causative factor for the eosinophilia cannot be verified during a certain period of time.
  • There have been only a few reported cases of this syndrome associated with malignant lymphoma.
  • We report a case of peripheral T-cell lymphoma-unspecified with hypereosinophilic syndrome.
  • A bone marrow aspiration demonstrated markedly increased eosinophils (24.8%), and a liver biopsy demonstrated infiltration by scattered eosinophils and atypical lymphoid cells, which were confirmed to be T-cell lymphoma cells.
  • This case was a distinctive presentation of peripheral T-cell lymphoma with hypereosinophilic syndrome, probably due to a paraneoplastic condition.
  • [MeSH-major] Hypereosinophilic Syndrome / etiology. Liver Neoplasms / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis. Pleural Effusion / etiology

  • Genetic Alliance. consumer health - Hypereosinophilic syndromes.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Emerg Med. 2001 Dec;8(4):325-30 [11785603.001]
  • [Cites] Pathol Oncol Res. 2001;7(4):292-7 [11882909.001]
  • [Cites] Eur J Haematol. 2003 Oct;71(4):303-6 [12950242.001]
  • [Cites] Ann Intern Med. 1968 Jun;68(6):1220-9 [5653621.001]
  • [Cites] Cancer. 1991 Feb 15;67(4):1064-9 [1991253.001]
  • [Cites] Ann Intern Med. 1982 Jul;97(1):78-92 [7046556.001]
  • [Cites] J Dermatol. 1983 Feb;10(1):75-80 [6345623.001]
  • [Cites] Cancer. 1988 Oct 15;62(8):1527-30 [3262407.001]
  • [Cites] Medicine (Baltimore). 1975 Jan;54(1):1-27 [1090795.001]
  • (PMID = 16646567.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3891066
  •  go-up   go-down


3. Tan BT, Warnke RA, Arber DA: The frequency of B- and T-cell gene rearrangements and epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. J Mol Diagn; 2006 Sep;8(4):466-75; quiz 527
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The frequency of B- and T-cell gene rearrangements and epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations.
  • We report on a series of 58 cases of angioimmunoblastic T-cell lymphoma (AILT) and 59 cases of peripheral T-cell lymphoma, unspecified (PTCL-NOS).
  • Subsets of cases from both diagnostic groups were complicated by associated B-cell proliferations, and we performed B- and T-cell clonality studies and in situ hybridization for Epstein-Barr virus (EBV) to investigate the relationship between B-cell proliferation, B-cell clonality, and EBV.
  • Using multiplex polymerase chain reaction assays based on the BIOMED-2 collaborative study, we detected TCRgamma T-cell clones in 78 and 81% of AILT and PTCL-NOS cases, respectively, and IGH B-cell clones in 34 and 35% of AILT and PTCL-NOS cases, respectively.
  • The majority of cases contained EBV-positive cells, including 50% of AILT and 57% of PTCL-NOS cases, and cases with B-cell proliferations were more often EBV-positive.
  • Although a relatively high rate of B-cell clonality has been shown for AILT, our findings for PTCL-NOS differ from previous reports in that B-cell clonality was relatively frequent.
  • Overall, a positive B-cell clone correlated, in part, with the presence of a B-cell proliferation but not with EBV.
  • Our findings demonstrate that B-cell clonality is a common finding in AILT and PTCL-NOS, and its presence should not negate the diagnosis established by morphologic, immunophenotypic, and clinical findings.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte. Herpesvirus 4, Human / genetics. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Cell Proliferation. Clone Cells. Female. Humans. Immunoglobulin Heavy Chains / genetics. Male. Middle Aged. Receptors, Antigen, T-Cell, gamma-delta / genetics

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2001 Nov;3(4):133-40 [11687596.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] J Mol Diagn. 2002 May;4(2):81-9 [11986398.001]
  • [Cites] J Pathol. 2002 Oct;198(2):171-80 [12237876.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2134-41 [12357368.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Am J Clin Pathol. 2002 Dec;118(6):848-54 [12472277.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):117-21 [12691150.001]
  • [Cites] J Mol Diagn. 2003 May;5(2):82-7 [12707372.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):807-13 [12802918.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 1983 Jun;61(6):1138-45 [6404327.001]
  • [Cites] Blood. 1986 Jan;67(1):1-11 [3079640.001]
  • [Cites] Am J Clin Pathol. 1986 Apr;85(4):490-3 [2420169.001]
  • [Cites] Leukemia. 1987 Mar;1(3):235 [3669744.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):549-56 [2849301.001]
  • [Cites] Clin Chim Acta. 1991 Apr;198(1-2):93-174 [1863986.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Histopathology. 1993 Feb;22(2):145-9 [8384155.001]
  • [Cites] Blood. 1993 Jul 1;82(1):217-23 [8391874.001]
  • [Cites] Histopathology. 1994 Feb;24(2):115-22 [8181803.001]
  • [Cites] Blood. 1994 Jul 15;84(2):574-81 [8025283.001]
  • [Cites] Virchows Arch. 1994;424(6):593-600 [8055152.001]
  • [Cites] J Pathol. 1994 Dec;174(4):233-42 [7884584.001]
  • [Cites] Leuk Lymphoma. 1995 Sep;19(1-2):1-12 [8574154.001]
  • [Cites] J Clin Pathol. 1995 Nov;48(11):1045-50 [8543629.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):956-64 [9706975.001]
  • [Cites] J Pathol. 1998 May;185(1):79-85 [9713363.001]
  • [Cites] Mol Diagn. 1999 Jun;4(2):119-33 [10462627.001]
  • [Cites] Hematol Oncol. 2004 Dec;22(4):169-77 [16134192.001]
  • [Cites] J Mol Diagn. 2005 Oct;7(4):495-503 [16237219.001]
  • [Cites] Am J Clin Pathol. 2000 Aug;114(2):236-47 [10941339.001]
  • [Cites] Mod Pathol. 2000 Dec;13(12):1269-79 [11144922.001]
  • [Cites] Diagn Mol Pathol. 2001 Jun;10(2):69-77 [11385314.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [CommentIn] J Mol Diagn. 2006 Sep;8(4):426-9; quiz 526-7 [16931581.001]
  • (PMID = 16931587.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Other-IDs] NLM/ PMC1867616
  •  go-up   go-down


Advertisement
4. Campidelli C, Sabattini E, Piccioli M, Rossi M, De Blasi D, Miraglia E, Rodriguez-Abreu D, Franscini LL, Bertoni F, Mazzucchelli L, Cavalli F, Zucca E, Pileri SA: Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases. Hum Pathol; 2007 May;38(5):787-92
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases.
  • We report on 2 composite lymphomas occurring in elderly patients, morphologically characterized by the combination of peripheral T-cell lymphoma (PTCL) unspecified and B-cell small lymphocytic lymphoma.
  • Immunohistochemistry provided objective confirmation of the coexistence of the 2 malignancies, as did molecular biology by revealing clonal T-cell receptor gamma and immunoglobulin heavy chain gene rearrangements.
  • One of the patients had no history of indolent lymphoma either at the personal and family level, whereas the other showed a strong familial predisposition, his mother and sister having suffered from B-cell chronic lymphocytic leukemia.
  • To the best of our knowledge, the simultaneous occurrence of PTCL unspecified and B-cell small lymphocytic lymphoma is an exceptional event; the possible pathogenetic correlations between the 2 neoplasms are discussed.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Lymphoma, B-Cell / complications. Lymphoma, T-Cell, Peripheral / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270243.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Venizelos J, Papadopoulos N, Lambropoulou M, Nikolaidou S, Bolioti S, Tamiolakis D: Metachronous extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) and peripheral T-cell lymphoma unspecified: histologic, immunophenotypic, and molecular documentation. Onkologie; 2005 Aug;28(8-9):423-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) and peripheral T-cell lymphoma unspecified: histologic, immunophenotypic, and molecular documentation.
  • BACKGROUND: Coexistence of B- and T-cell lymphoid malignancies has been reported sporadically.
  • CASE REPORT: A 68-year-old woman developed a lymphoid neoplasm in the large intestine and a second lymphoid neoplasm in the esophagus, 24 months after the diagnosis of the first lymphoma.
  • Immunophenotypic analyses were consistent with extranodal marginal zone B-cell mucosa-associated lymphoid tissue type (MALT type) and peripheral T-cell unspecified lymphomas in the large intestine and the esophagus, respectively.
  • The molecular analysis confirmed the B-clonal genotype of the first lymphoma, and disclosed a biclonal genotype of the second one (composite T- and B-cell lymphoma).
  • CONCLUSION: B- and T-cell neoplasms represent two distinct malignancies rather than progression of the same neoplastic clone.
  • [MeSH-major] Colonic Neoplasms / pathology. Esophageal Neoplasms / pathology. Immunophenotyping. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Aged. Antibodies, Viral / blood. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Biomarkers, Tumor / genetics. Biopsy. Epstein-Barr Virus Infections / genetics. Epstein-Barr Virus Infections / immunology. Epstein-Barr Virus Infections / pathology. Esophagus / pathology. Female. Gene Rearrangement / genetics. Genes, T-Cell Receptor gamma. Herpesvirus 4, Human / immunology. Humans. Immunoglobulin M / blood. Intestinal Mucosa / pathology. Mitotic Index. Neoplasm Invasiveness. Polymerase Chain Reaction. T-Lymphocytes / immunology. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160405.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Biomarkers, Tumor; 0 / Immunoglobulin M
  •  go-up   go-down


6. Prochazka V, Trneny M, Pytlik R, Vasova I, Kral Z, Belada D, Kozak T, Kubackova K, Siffnerova H, Matuska M, Lysy M, Bolomska I, Petrakova K, Otavova B, Pribylova J, Svecova J, Papajik T, Hamouzova M, Petrova M, Zapletalova J, Langova K: Peripheral T-cell lymphoma, unspecified--the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun;151(1):103-7
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma, unspecified--the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry.
  • BACKGROUND: Peripheral T-cell lymphoma, unspecified (PTCL-US) is one of the entities from the infrequent family of nodal mature T-cell lymphomas.
  • Published data are limited to retrospective, mostly single-center studies or reviews and usually include more lymphoma subtypes.
  • METHOD: Czech Lymphoma Study Group is a national scientific organization which provides an on-line database registry which collects a data about almost all new diagnosed lymphoma patients since year 2000.
  • The median age was 59 years (25-81), chemotherapy (CHT) was administered in 56 of the 63 patients: anthracyclin-based CHT in 51%, intensive CHT in 21% and non-anthracyclin regimen was applied in 13% of the patients.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690750.001).
  • [ISSN] 1213-8118
  • [Journal-full-title] Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
  • [ISO-abbreviation] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


7. Grogg KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A: Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol; 2006 Aug;19(8):1101-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified.
  • The germinal center T-helper cell has been proposed as the cell of origin for angioimmunoblastic T-cell lymphoma.
  • Our recent report of expression of CXCL13, a chemokine critical for germinal center formation and one of the most highly upregulated genes in the germinal center T-helper cell subset, in the majority of angioimmunoblastic T-cell lymphoma cases, provided further support for this theory.
  • To determine the specifity of this marker for angioimmunoblastic T-cell lymphoma, we evaluated CXCL13 expression in 26 nodal-based peripheral T-cell lymphomas and 14 lymph nodes showing paracortical lymphoid hyperplasia.
  • By WHO classification criteria, 20 of the lymphoma cases were considered peripheral T-cell lymphoma, unspecified, and six were reclassified as angioimmunoblastic T-cell lymphoma after immunohistochemical detection of disorganized follicular dendritic cell meshworks.
  • Combining the results of our studies, 31 of 35 angioimmunoblastic T-cell lymphoma cases (89%) showed CXCL13 expression, in contrast to two out of 20 peripheral T-cell lymphoma, unspecified cases (10%).
  • The two peripheral T-cell lymphoma, unspecified cases that were positive for CXCL13 showed a Lennert lymphoma-like histology.
  • While these cases did not meet all histologic criteria for angioimmunoblastic T-cell lymphoma, they did show an increase in EBV-positive B cells, suggesting they may be histologic variants of angioimmunoblastic T-cell lymphoma.
  • In conclusion, CXCL13 expression is a distinctive feature of angioimmunoblastic T-cell lymphoma, providing further support for the germinal center T-helper cell as the cell of origin for this neoplasm.
  • Given its specificity when compared to cases of peripheral T-cell lymphoma, unspecified as well as paracortical lymphoid hyperplasia, it may be a useful marker in the diagnosis of angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Chemokines, CXC / metabolism. Germinal Center / metabolism. Immunoblastic Lymphadenopathy / metabolism. Lymphoma, Follicular / metabolism. Lymphoma, T-Cell, Peripheral / metabolism. T-Lymphocytes, Helper-Inducer / metabolism

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Mod Pathol. 2007 Feb;20(2):277. Attygale, Ayoma D [corrected to Attygalle, Ayoma D]
  • (PMID = 16680156.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Chemokines, CXC
  •  go-up   go-down


8. Yu T, Wang ZY, Ma CC: [A case of peripheral T cell lymphomas-unspecified in vertebra canal]. Beijing Da Xue Xue Bao; 2007 Aug 18;39(4):343-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of peripheral T cell lymphomas-unspecified in vertebra canal].
  • Peripheral T cell lymphomas-unspecified (PTCL-U) is an uncommon malignant tumor, accounting for 5%-7% of non-Hodgkin's lymphoma.
  • Initial diagnosis was lymphoma, multiple systems involved.
  • Early diagnosis of peripheral T cell lymphomas-unspecified was difficult and easily misdiagnosed with poor prognosis.
  • [MeSH-major] Epidural Neoplasms. Lymphoma, T-Cell, Peripheral

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657255.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Wang W, Ji FS, Chen HS, Zhang NX, Zhang SY, Zhang L, Liu EB, Yang QY, Fang LH, Sun FJ: [Clinicopathologic features of peripheral T-cell lymphoma, unspecified with follicular pattern]. Zhonghua Bing Li Xue Za Zhi; 2009 Apr;38(4):248-52
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic features of peripheral T-cell lymphoma, unspecified with follicular pattern].
  • OBJECTIVE: To study the clinicopathologic features of peripheral T-cell lymphoma, unspecified (PTL-U) with follicular pattern.
  • T-cell receptor and immunoglobulin heavy chain gene rearrangement studies were conducted by polymerase chain reaction-based method.
  • The male-to-female ratio was 1.57:1 in lymphoma group.
  • All of the lymphoma patients presented with superficial lymphadenopathy, with (8/18) or without B symptoms.
  • Histologically, the lymphoma was characterized by follicles of various sizes and shapes.
  • The T zones were expanded by medium-sized lymphoma cells which contained clear cytoplasm and irregular nuclei.
  • Immunohistochemical study confirmed that the lymphoma cells were of T-lineage.
  • T-cell receptor gene rearrangement was demonstrated in 71.4% (10/14) of the lymphoma cases.
  • [MeSH-major] Ki-67 Antigen / metabolism. Lymphoma, Follicular / pathology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD3 / metabolism. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Gene Rearrangement, T-Lymphocyte. Humans. Lymphatic Diseases / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Young Adult

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575896.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Ki-67 Antigen
  •  go-up   go-down


10. Asano N, Suzuki R, Kagami Y, Ishida F, Kitamura K, Fukutani H, Morishima Y, Takeuchi K, Nakamura S: Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol; 2005 Oct;29(10):1284-93
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified.
  • Expression of TIA-1 and granzyme B was examined for 100 cases of nodal peripheral T-cell lymphoma, unspecified (PTCL-U) to assess clinicopathologic significance of CM.
  • The CM-positive group showed higher distribution of the International Prognostic Index (P = 0.009) and the Prognostic Index for T-cell lymphoma (P = 0.004) scores than CM-negative group.
  • [MeSH-major] Lymphoma, T-Cell / metabolism. RNA-Binding Proteins / biosynthesis. Serine Endopeptidases / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160469.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA-Binding Proteins; 148592-68-1 / TIAL1 protein, human; EC 3.4.21.- / GZMB protein, human; EC 3.4.21.- / Granzymes; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


11. Castillo JJ, Morales D, Quinones P, Cotrina E, Desposorio C, Beltran B: Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma; 2010 Oct;51(10):1822-8
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified.
  • Peripheral T-cell lymphoma, unspecified (PTCLU) is the most common T-cell lymphoma variant.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology. Lymphopenia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Oct;51(10):1773-4 [20849382.001]
  • (PMID = 20849388.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Attygalle AD, Chuang SS, Diss TC, Du MQ, Isaacson PG, Dogan A: Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology; 2007 Mar;50(4):498-508
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics.
  • AIMS: To identify distinguishing histological, immunophenotypic and molecular genetic features between angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma (PTL).
  • METHODS: Nodal T-cell lymphomas examined (n =137), included AITL (n = 89), PTL (n = 22), anaplastic large cell lymphoma (n = 16) and 'AITL/PTL indeterminate' (n = 10) with overlapping features between AITL and PTL, showing morphology typical of AITL but lacking follicular dendritic cell expansion.
  • Immunohistochemistry for CD3, CD20, CD21 and CD10, in situ hybridization for Epstein-Barr virus encoded RNA (EBER) and polymerase chain reaction for T-cell and B-cell clonality analysis were performed.
  • Detection of T-cell clonality was significantly higher in AITL (90%) compared with PTLu (59%).
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis
  • [MeSH-minor] Antigens, CD20 / metabolism. Antigens, CD3 / metabolism. B-Lymphocytes / pathology. Clone Cells. Diagnosis, Differential. Gene Rearrangement. Herpesvirus 4, Human / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Immunophenotyping. Neprilysin / metabolism. Polymerase Chain Reaction. RNA, Viral / analysis. Receptors, Antigen, T-Cell, gamma-delta / genetics. Receptors, Complement 3d / metabolism. Sensitivity and Specificity. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448026.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Immunoglobulin Heavy Chains; 0 / RNA, Viral; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


13. Hayabuchi T, Hashimoto K, Matsumoto S, Yamamura M, Ueda Y, Yamasaki A, Chikumi H, Shimizu E: [Peripheral T-cell lymphoma unspecified with remarkably extensive airspace consolidations and ground-glass opacities of bilateral lung fields]. Nihon Kokyuki Gakkai Zasshi; 2009 Nov;47(11):1051-6
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peripheral T-cell lymphoma unspecified with remarkably extensive airspace consolidations and ground-glass opacities of bilateral lung fields].
  • Bronchoalveolar lavage were performed, showing abnormal lymphocytes which indicated infiltration of malignant lymphoma.
  • Furthermore, a biopsy of the left inguinal lymph node revealed T-cell lymphoma.
  • We finally diagnosed his pulmonary lesions as involvement of peripheral T-cell lymphoma unspecified in consideration of immunohistochemical estimation.
  • Pulmonary involvement of malignant lymphoma is thought to be relatively uncommon.
  • Because these radiological findings may indicate a severe status of lymphoma, it is necessary to diagnose and treat them immediately.
  • [MeSH-major] Lung / radiography. Lymphoma, T-Cell, Peripheral / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19994604.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Ryan AJ, Robson A, Hayes BD, Sheahan K, Collins P: Primary cutaneous peripheral T-cell lymphoma, unspecified with an indolent clinical course: a distinct peripheral T-cell lymphoma? Clin Exp Dermatol; 2010 Dec;35(8):892-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous peripheral T-cell lymphoma, unspecified with an indolent clinical course: a distinct peripheral T-cell lymphoma?
  • Primary cutaneous peripheral T-cell lymphomas (PTL), unspecified, are rare lymphomas, with a poor prognosis.
  • We report a case of PTL, unspecified occurring on the nose.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / pathology. Lymphoma, T-Cell, Peripheral / pathology. Nose Neoplasms / pathology. Skin Neoplasms / pathology


15. Dueck GS, Chua N, Prasad A, Stewart D, White D, vanderJagt R, Johnston JB, Belch A, Reiman T: Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases. J Clin Oncol; 2009 May 20;27(15_suppl):8524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases.
  • : 8524 Background: Novel therapies are needed to improve outcomes in T-cell lymphomas.
  • We report the interim results of a prospective multicenter trial evaluating lenalidomide in T-cell lymphomas.
  • METHODS: Patients with relapsed and refractory T-cell lymphomas other than mycosis fungoides were prescribed oral lenalidomide (25mg daily) on days 1 to 21 of each 28 day cycle, with standardized dose reductions for toxicity.
  • The histology was peripheral T-cell unspecified (PTCL-u, n=10), angioimmunoblastic (n=7), anaplastic large cell (n=5), enteropathic T-cell (n=1) and hepatosplenic gamma/delta (n=1).
  • Median number of prior therapies was 1 (range, 0-4), and three had prior autologous stem cell transplant.
  • CONCLUSIONS: In relapsed and refractory T-cell lymphomas, oral lenalidomide monotherapy has clinical activity and toxicity is consistent with the known profile of lenalidomide.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960899.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Savage KJ: Aggressive peripheral T-cell lymphomas (specified and unspecified types). Hematology Am Soc Hematol Educ Program; 2005;:267-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive peripheral T-cell lymphomas (specified and unspecified types).
  • Peripheral T-cell lymphomas (PTCLs) are a biologically diverse and uncommon group of diseases.
  • Compared to their B-cell counterparts, PTCLs remain largely unexplored and the optimal treatment ill-defined due to disease rarity and biological heterogeneity.
  • For the majority of PTCL subtypes, prognosis is poor with a 5-year overall survival of approximately 30% in most series.The notable exception is ALK-positive anaplastic large-cell lymphoma (ALK-pos ALCL), which has a superior outcome.
  • The international prognostic index can be used to some extent to define risk groups within some PTCL subtypes, including PTCL unspecified (PTCLUS).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Hematology Am Soc Hematol Educ Program. 2006;()
  • (PMID = 16304391.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Rodriguez-Abreu D, Filho VB, Zucca E: Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review. Hematol Oncol; 2008 Mar;26(1):8-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review.
  • Peripheral T-cell lymphomas (PTCL) comprises a heterogeneous group of haematological tumours, which originate from mature T-cells, and constitute less than 15% of all non-Hodgkin's lymphomas (NHLs) in adults.
  • The current WHO classification recognizes nine distinct clinicopathologic peripheral T-cell NHLs, being the 'unspecified variant' (PTCL-U) the most common subtype.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Gene Expression Profiling. Hematopoietic Stem Cell Transplantation. Humans. Immunophenotyping. Immunotoxins / therapeutic use. Prognosis. Proteasome Inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050364.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Immunotoxins; 0 / Proteasome Inhibitors
  • [Number-of-references] 120
  •  go-up   go-down


18. Lee Y, Uhm JE, Lee HY, Park MJ, Kim H, Oh SJ, Jang JH, Kim K, Jung CW, Ahn YC, Park K, Ko YH, Kim WS: Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified". Ann Hematol; 2009 Feb;88(2):111-9
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified".
  • The purpose of this retrospective study was to investigate clinical features and treatment outcomes in patients with peripheral T cell lymphoma-unspecified (PTCL-U).
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648812.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Fujiwara SI, Yamashita Y, Nakamura N, Choi YL, Ueno T, Watanabe H, Kurashina K, Soda M, Enomoto M, Hatanaka H, Takada S, Abe M, Ozawa K, Mano H: High-resolution analysis of chromosome copy number alterations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified, with single nucleotide polymorphism-typing microarrays. Leukemia; 2008 Oct;22(10):1891-8
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution analysis of chromosome copy number alterations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified, with single nucleotide polymorphism-typing microarrays.
  • Angioimmunoblastic T-cell lymphoma (AILT) and peripheral T-cell lymphoma, unspecified (PTCL-u) are relatively frequent subtypes of T- or natural killer cell lymphoma.
  • [MeSH-major] Chromosome Aberrations. Loss of Heterozygosity. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Oligonucleotide Array Sequence Analysis. Polymorphism, Single Nucleotide

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633432.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CARD Signaling Adaptor Proteins; 0 / DNA-Binding Proteins; 0 / IKZF2 protein, human; 0 / MYCBP protein, human; 0 / Transcription Factors; 148971-36-2 / Ikaros Transcription Factor; EC 3.4.24.11 / Neprilysin; EC 4.6.1.2 / CARD11 protein, human; EC 4.6.1.2 / Guanylate Cyclase
  •  go-up   go-down


20. Zucca E, Zinzani PL: Understanding the group of peripheral T-cell lymphomas, unspecified. Curr Hematol Rep; 2005 Jan;4(1):23-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding the group of peripheral T-cell lymphomas, unspecified.
  • Presumably diverse cases are at present lumped under the heading peripheral T-cell lymphoma, not otherwise categorized, or unspecified (PTCL-U), which comprise the largest group of T-cell neoplasms in Western countries.
  • Hopefully, some progress can be expected from the novel sophisticated and powerful genomic and proteomics technologies, which may uncover the group of T-cell neoplasms, and perhaps identify some specific disease entities.
  • The treatments used for diffuse large B-cell lymphoma have produced disappointing results in peripheral T-cell lymphoma.
  • Novel strategies need to be developed and specific regimens including active agents in peripheral T-cell lymphoma should be investigated.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / classification
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Case Management. Female. Gene Rearrangement, T-Lymphocyte. Humans. Immunophenotyping. Killer Cells, Natural / pathology. Lymphoma, T-Cell, Cutaneous / classification. Male. Middle Aged. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, gamma-delta / genetics. Survival Analysis. T-Lymphocyte Subsets / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15610656.001).
  • [ISSN] 1541-0714
  • [Journal-full-title] Current hematology reports
  • [ISO-abbreviation] Curr. Hematol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Number-of-references] 61
  •  go-up   go-down


21. Kitagawa J, Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, Kasahara S, Yamada T, Sawada M, Takahashi T, Shimizu M, Takami T, Moriwaki H: Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). J Cancer Res Clin Oncol; 2009 Jan;135(1):53-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U).
  • PURPOSE: The aim of this study was to assess the prognostic factors of peripheral T-cell lymphoma, unspecified (PTCL-U).
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / blood. Receptors, Interleukin-2 / blood

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Eur J Haematol. 2000 Sep;65(3):195-202 [11007056.001]
  • [Cites] Eur J Haematol. 2006 Sep;77(3):217-25 [16856931.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Feb;130(2):107-13 [14648210.001]
  • [Cites] Arch Dermatol. 1996 Jan;132(1):42-7 [8546482.001]
  • [Cites] Hematol Oncol. 2007 Sep;25(3):107-14 [17457949.001]
  • [Cites] Med Pediatr Oncol. 1994;22(4):261-8 [8107658.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1921-5 [10961895.001]
  • [Cites] Ann Intern Med. 1997 Aug 1;127(3):186-94 [9245223.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Feb;131(2):73-9 [15503137.001]
  • [Cites] Haematologica. 1997 Mar-Apr;82(2):171-7 [9175321.001]
  • [Cites] J Immunol. 1985 Nov;135(5):3172-7 [3930598.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1202-10 [11222361.001]
  • [Cites] Br J Haematol. 1994 Dec;88(4):770-7 [7819101.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Cancer Chemother Pharmacol. 1987;20(2):151-4 [3478154.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Lymphokine Res. 1982;1(2):37-43 [6821402.001]
  • [Cites] J Exp Med. 1983 Dec 1;158(6):1895-911 [6606011.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Leuk Lymphoma. 1998 Oct;31(3-4):351-7 [9869199.001]
  • [Cites] Br J Haematol. 1996 Apr;93(1):45-52 [8611474.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3541-50 [10552965.001]
  • [Cites] Leukemia. 2003 Jan;17(1):196-202 [12529678.001]
  • [Cites] Eur J Haematol. 2002 Jun;68(6):354-61 [12225393.001]
  • [Cites] Am J Hematol. 2000 Aug;64(4):257-61 [10911377.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3334-9 [10552942.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):423-9 [10458261.001]
  • [Cites] N Engl J Med. 1997 Aug 21;337(8):529-34 [9262496.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1131-7 [9060555.001]
  • (PMID = 18592269.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Interleukin-2
  •  go-up   go-down


22. Yu YX, Shi YK, He XH, Zhou LQ, Zhou SY, Dong M, Feng FY, Sun Y: [Clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified: a report of 78 cases]. Zhonghua Yi Xue Za Zhi; 2007 Oct 16;87(38):2714-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified: a report of 78 cases].
  • OBJECTIVE: To summarize the clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified (PTCL-US).
  • METHODS: The medical records of 78 patients with PTCL-US classified according to the revised European and American lymphoma (REAL) or WHO criteria, 58 males and 20 females, aged 39 (9 - 75), 46 of them (59%) being at the stages III/VI and 40 cases (51.2%) with extranodal involvement), treated from Jan 1994 to Dec 2004 in the Cancer Hospital/Institute, Chinese Academy of Medical Sciences, were retrospectively analyzed.
  • Achieving CR or PR after first-line treatment, 13 cases received autologous peripheral blood stem cell transplantation (APBSCT).
  • International prognostic index and prognostic index for peripheral T-cell lymphoma both predicted the overall survival.
  • CONCLUSION: A rare lymphoma with aggressive presentation, PTCL-US responds poorly to conventional treatment.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / surgery

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18167252.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


23. Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A: Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia; 2006 Feb;20(2):313-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma.
  • Among peripheral T-cell lymphomas (PTCL), the heterogeneous category of unspecified PTCL represents the most common subtype.
  • Nevertheless, recurrent chromosomal translocations are unknown in this aggressive type of lymphoma.
  • Here we describe a novel t(5;9)(q33;q22) in unspecified PTCL.
  • ITK-SYK transcripts were detected in five of 30 (17%) unspecified PTCL, but not in cases of angioimmunoblastic T-cell lymphoma (n=9) and anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma (n=7).
  • Three of the five t(5;9)(q33;q22)+ unspecified PTCL shared a very similar histological pattern with predominant involvement of lymphoid follicles and the same CD3+CD5+CD4+bcl-6+CD10+ immunophenotype.
  • These results demonstrate the presence of a recurrent t(5;9)(q33;q22) in a subset of unspecified PTCL, which may represent a novel distinct subgroup of PTCL.
  • [MeSH-major] Chromosomes, Human, Pair 5 / genetics. Chromosomes, Human, Pair 9 / genetics. Intracellular Signaling Peptides and Proteins / genetics. Lymphoma, Non-Hodgkin / genetics. Lymphoma, T-Cell, Peripheral / genetics. Oncogene Proteins, Fusion / genetics. Protein-Tyrosine Kinases / genetics

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2006 Feb;20(2):208-9 [16307012.001]
  • (PMID = 16341044.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Oncogene Proteins, Fusion; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 2.7.10.2 / emt protein-tyrosine kinase
  •  go-up   go-down


24. Thorns C, Bastian B, Pinkel D, Roydasgupta R, Fridlyand J, Merz H, Krokowski M, Bernd HW, Feller AC: Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach. Genes Chromosomes Cancer; 2007 Jan;46(1):37-44
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach.
  • Angioimmunoblastic T-cell lymphoma (AILT) is a histopathologically well-defined entity.
  • However, despite a number of cytogenetic studies, the genetic basis of this lymphoma entity is not clear.
  • Moreover, there is an overlap to some cases of peripheral T-cell lymphoma unspecified (PTCL-u) in respect to morphological and genetic features.
  • In conclusion, CGH revealed common genetic events in peripheral T-cell lymphomas as well as peculiar differences between AILT and PTCL-u.
  • [MeSH-major] Chromosome Aberrations. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17044049.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Eum EA, Kim H, Kim YM, Woo SJ, Cho JH, Min YJ, Park JH: Anorectal and gastric peripheral T-cell lymphoma, unspecified in a non-AIDS patient. Korean J Intern Med; 2006 Dec;21(4):262-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anorectal and gastric peripheral T-cell lymphoma, unspecified in a non-AIDS patient.
  • Anorectum is a rare location for malignant lymphoma.
  • Involvement of is rare even for the lynphoma associated with acquired immune deficiency syndrome (AIDS), and AIDS has a relatively increased frequency of anorectal lymphoma.
  • Most lymphomas in AIDS patients are of a B-cell origin, and T-cell lymphoma of the gastrointestinal tract is extremely rare.
  • We report here on a case of anorectal and gastric peripheral T-cell lymphoma, unspecified (PTCLu) in a non-AIDS patient.
  • There was no lymphoma involved in the bone marrow.
  • He underwent systemic chemotherapy and upfront autologous stem cell transplantation.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Lymphoma, T-Cell, Peripheral / pathology. Rectal Neoplasms / pathology. Stomach Neoplasms / pathology


26. Piccaluga PP, Agostinelli C, Gazzola A, Mannu C, Bacci F, Sabattini E, Pileri SA: Prognostic markers in peripheral T-cell lymphoma. Curr Hematol Malig Rep; 2010 Oct;5(4):222-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic markers in peripheral T-cell lymphoma.
  • Based on their own experience and knowledge of the literature, the authors review the pathobiological characteristics of peripheral T-cell lymphomas (PTCLs), focusing on the available prognostic indicators.
  • However, it is not so satisfactory for the two commonest PTCLs, PTCL not otherwise specified (PTCL/NOS) and angioimmunoblastic T-cell lymphoma (AITL), for which novel scores, possibly based on the biologic features of the tumors, have been explored.
  • An Italian cooperative group proposed a revision of the IPI for PTCL unspecified (PTCL-U), the Prognostic Index for PTCL-U (PIT), which includes age, performance status, LDH, and bone marrow involvement.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / diagnosis

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2009 Jul;94(7):1036-7 [19508975.001]
  • [Cites] Br J Haematol. 2010 Feb;148(3):402-12 [19863542.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1026-36 [19965671.001]
  • [Cites] Blood. 2010 Feb 11;115(6):1226-37 [19965620.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1583-90 [20159827.001]
  • [Cites] N Engl J Med. 2010 Apr 15;362(15):1417-29 [20393178.001]
  • [Cites] Ann Oncol. 2010 May;21(5):1032-40 [19850638.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90 [12182990.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2213-9 [12750155.001]
  • [Cites] Blood. 2004 Jan 1;103(1):216-21 [12933580.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1837-48 [15111330.001]
  • [Cites] Blood. 2004 Jul 1;104(1):243-9 [15031209.001]
  • [Cites] Cancer. 2004 Jun 25;102(3):174-85 [15211477.001]
  • [Cites] Curr Treat Options Oncol. 2004 Aug;5(4):289-303 [15233906.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4971-82 [15297397.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1097-107 [15195107.001]
  • [Cites] Leuk Res. 2004 Dec;28(12):1287-92 [15475070.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):375-87 [15494863.001]
  • [Cites] Histopathology. 1993 Apr;22(4):303-10 [8514273.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):909-16 [8101471.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Anal Quant Cytol Histol. 1996 Oct;18(5):337-44 [8908304.001]
  • [Cites] Histopathology. 2001 Mar;38(3):250-70 [11260307.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):821-9 [9217183.001]
  • [Cites] Cell Prolif. 1997 Jan;30(1):37-47 [9332493.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):973-8 [9402170.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Anat Pathol. 1998;3:77-145 [10389582.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):849-55 [10414505.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):440 [15925824.001]
  • [Cites] Hematology. 2005 Jun;10(3):237-45 [16019472.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1063-9 [16079105.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):29-38 [16173960.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2254-63 [16270046.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):612-8 [16380410.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1560-70 [16288225.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4500-7 [16484591.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4163-9 [16902151.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2156-64 [17077326.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Haematologica. 2007 Apr;92(4):566-7 [17488672.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):38-44 [17536305.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3250-4 [17545530.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3321-9 [17577022.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3345-51 [17634410.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10703-10 [18006812.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] J Clin Pathol. 2008 Nov;61(11):1160-7 [18755717.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1071-4 [18955564.001]
  • [Cites] Histopathology. 2009 Mar;54(4):478-85 [19309400.001]
  • [Cites] Ann Oncol. 2009 Apr;20(4):715-21 [19150954.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3931-7 [19029440.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4016-26 [19131553.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):583-92 [9261528.001]
  • [ErratumIn] Curr Hematol Malig Rep. 2010 Oct;5(4):239
  • (PMID = 20690003.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.- / Lactate Dehydrogenases
  • [Other-IDs] NLM/ PMC2948168
  •  go-up   go-down


27. Miyazaki K, Yamaguchi M, Imai H, Kobayashi T, Tamaru S, Nishii K, Yuda M, Shiku H, Katayama N: Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. Blood; 2009 Jan 29;113(5):1071-4
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma.
  • The gene expression profile of peripheral gammadelta T-cell lymphoma (gammadeltaTCL) has not been investigated.
  • Using oligonucleotide microarrays, we analyzed total RNA from 7 patients with gammadeltaTCL (4 hepatosplenic, 1 cutaneous, 1 intestinal, and 1 thyroidal) and 27 patients with alphabetaTCL (11 peripheral TCL-unspecified, 15 angioimmunoblastic TCL, and 1 hepatosplenic).
  • We identified a T-cell receptor signature gene set, which accurately classified gammadeltaTCL and alphabetaTCL.
  • One case of hepatosplenic alphabetaTCL was placed in the gammadeltaTCL grouping. gammadeltaTCL signature genes included genes encoding killer cell immunoglobulin-like receptors and killer cell lectin-like receptors.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Lymphoma, T-Cell / metabolism. Neoplasm Proteins / biosynthesis. Receptors, Antigen, T-Cell, gamma-delta

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955564.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


28. Rodríguez-Pinilla SM, Atienza L, Murillo C, Pérez-Rodríguez A, Montes-Moreno S, Roncador G, Pérez-Seoane C, Domínguez P, Camacho FI, Piris MA: Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol; 2008 Dec;32(12):1787-99
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma with follicular T-cell markers.
  • INTRODUCTION: Peripheral T-cell lymphomas (PTCLs) in western countries are uncommon tumors with unfavorable prognosis.
  • They may be subclassified as anaplastic large-cell lymphomas (ALCLs), angioimmunoblastic-T-cell lymphomas (AITLs), or unspecified peripheral T-cell lymphomas (PTCLs-U).
  • The aim of this study was to establish whether other PTCL subgroups also express TFH cell markers.
  • PD-1-positive cases, which did not fulfill all the criteria for AITL, were further evaluated in whole-tissue sections for another 12 immunohistochemical markers, including the TFH cell markers CXCL13, CD10, and BCL6.
  • Clonal Ig and T-cell receptor rearrangements and Epstein-Barr virus-encoded RNA expression were also evaluated.
  • RESULTS: Twenty-five out of 87 non-AITL cases (28.75%) showed PD-1 immunostaining.
  • All cases expressed at least 2 TFH cell markers.
  • Of the remainder, 1 was considered to be early AITL, 1 was diagnosed as ALCL-anaplastic lymphoma kinase-negative, and 4 of the other 6 PTCLs-U had morphology consistent with lymphoepithelioid (Lennert's) lymphoma.
  • CONCLUSIONS: TFH cell markers, especially PD-1, were expressed in a subset of PTCLs not classified as AITL, although most of them shared some morphologic features with AITL.
  • This suggests that the spectrum of AITL may be wider than previously thought, possibly including cases of lymphoepithelioid (Lennert's) lymphoma.
  • [MeSH-major] Antigens, CD / biosynthesis. Apoptosis Regulatory Proteins / biosynthesis. Biomarkers / analysis. Lymphoma, T-Cell, Peripheral / classification. Lymphoma, T-Cell, Peripheral / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemokine CXCL13 / biosynthesis. Female. Gene Rearrangement, T-Lymphocyte. Humans. Immunohistochemistry. In Situ Hybridization. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Neprilysin / biosynthesis. Programmed Cell Death 1 Receptor. Proto-Oncogene Proteins / biosynthesis. Repressor Proteins / biosynthesis. T-Lymphocytes, Helper-Inducer / metabolism. T-Lymphocytes, Helper-Inducer / pathology. Tissue Array Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18779728.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Apoptosis Regulatory Proteins; 0 / BCOR protein, human; 0 / Biomarkers; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


29. Raja MS, Gupta D, Ball RY, Hemmant B: Systemic T-cell lymphoma presenting as an acute nonresolving eyelid mass. Ophthal Plast Reconstr Surg; 2010 May-Jun;26(3):212-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic T-cell lymphoma presenting as an acute nonresolving eyelid mass.
  • Histopathologic examination revealed a peripheral T-cell lymphoma of unspecified type, which was stage 3 on staging.
  • A brief literature review of ocular adnexal T-cell lymphomas is presented.
  • [MeSH-major] Cysts / diagnosis. Eyelid Neoplasms / diagnosis. Lymphoma, T-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20489551.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Okabe S, Miyazawa K, Iguchi T, Sumi M, Takaku T, Ito Y, Kimura Y, Serizawa H, Mukai K, Ohyashiki K: Peripheral T-cell lymphoma together with myelofibrosis with elevated plasma transforming growth factor-beta1. Leuk Lymphoma; 2005 Apr;46(4):599-602
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma together with myelofibrosis with elevated plasma transforming growth factor-beta1.
  • However, there are only a few reports showing an association between T-cell lymphoma and myelofibrosis.
  • We report a case of peripheral T-cell lymphoma, unspecified (diffuse large cell) type, involving the bone marrow that was associated with severe myelofibrosis.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / complications. Primary Myelofibrosis / complications. Transforming Growth Factor beta / analysis

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019489.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


31. Shimizu D, Taki T, Utsunomiya A, Nakagawa H, Nomura K, Matsumoto Y, Nishida K, Horiike S, Taniwaki M: Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma. Int J Hematol; 2007 Apr;85(3):212-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma.
  • We analyzed NOTCH1 gene mutation in 53 adults with mature T-cell leukemia/lymphoma: 21 patients with adult T-cell leukemia (ATL), 25 with T-cell non-Hodgkin's lymphoma (T-NHL), and 7 with T-cell prolymphocytic leukemia.
  • We detected a nonsense mutation, C7249T (resulting in Q2417X, where X is a termination codon) in the PEST domain of NOTCH1 in an ATL patient and detected a 3-bp deletion (positions 7234-7236) that resulted in deletion of a proline codon at codon 2412 in the PEST domain of NOTCH1 in a patient with a T-NHL, peripheral T-cell lymphoma-unspecified (PTCL-u).
  • These findings suggest that nonsense mutation in the PEST domain in the ATL case was associated with NOTCH1 signaling through a pathway different from that for T-cell acute lymphoblastic leukemia (T-ALL).
  • Although NOTCH1 mutation occurs infrequently in mature T-cell leukemia/lymphoma, NOTCH1 may be involved in leukemogenesis associated with various forms of T-cell leukemia/lymphoma rather than only with T-ALL.
  • [MeSH-major] Codon, Nonsense. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Receptor, Notch1 / genetics

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Sep 15;104(6):1696-702 [15187027.001]
  • [Cites] Blood. 2002 May 1;99(9):3398-403 [11964309.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34371-8 [11425854.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7505-15 [11003647.001]
  • [Cites] Virchows Arch. 2005 Apr;446(4):416-20 [15756589.001]
  • [Cites] Int J Hematol. 2005 Nov;82(4):277-84 [16298815.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1091-6 [15205204.001]
  • [Cites] Int J Hematol. 2005 Nov;82(4):295-301 [16298817.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):655-64 [12509463.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1255-64 [16210342.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1841-3 [16079893.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1906-13 [10961893.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Immunity. 1999 Sep;11(3):299-308 [10514008.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):702-5 [10468859.001]
  • [Cites] Blood. 2004 Dec 1;104(12 ):3697-704 [15292061.001]
  • [Cites] Nat Immunol. 2005 Jul;6(7):680-8 [15991363.001]
  • [Cites] Nature. 2005 Sep 8;437(7056):270-4 [16025100.001]
  • [Cites] Blood. 1994 Jan 15;83(2):505-11 [8286748.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3097-105 [15251982.001]
  • [Cites] Electrophoresis. 2001 Oct;22(18):4016-22 [11700735.001]
  • [Cites] Pathol Int. 2000 Sep;50(9):696-702 [11012982.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4642-51 [16738328.001]
  • [Cites] Cell. 1997 Mar 21;88(6):833-43 [9118226.001]
  • [Cites] Blood. 2004 Jul 15;104(2):328-35 [15044256.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(11):3928-41 [10805736.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Feb;117(1):71-9 [10700871.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3898-906 [16118316.001]
  • [Cites] Trends Biochem Sci. 1996 Jul;21(7):267-71 [8755249.001]
  • [Cites] Cell. 2004 May 14;117(4):515-26 [15137944.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3043-9 [16707600.001]
  • [Cites] Leukemia. 2003 Apr;17(4):738-45 [12682631.001]
  • [Cites] Cell. 1996 Nov 1;87(3):483-92 [8898201.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1627-32 [11587222.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9265-73 [15485896.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3793-9 [11739188.001]
  • (PMID = 17483057.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1
  •  go-up   go-down


32. Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T, Takase K, Henzan H, Kato K, Takenaka K, Fukuda T, Harada N, Nagafuji K, Teshima T, Akashi K, Harada M, Eto T, Fukuoka Blood and Marrow Transplantation Group: Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant; 2010 Feb;45(2):311-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group.
  • Peripheral T-cell lymphoma (PTCL) is generally characterized by poor prognosis after conventional chemotherapy compared with aggressive B-cell lymphoma.
  • Eleven patients were histologically typed as angioimmunoblastic, nine as anaplastic large-cell lymphoma, seven as natural killer/T-cell lymphoma and twelve as PTCL unspecified.
  • Clinical conditions at transplantation were complete response (CR) in 27 patients and non-CR in 12 patients.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / therapy. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597416.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Windsor R, Stiller C, Webb D: Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years. Pediatr Blood Cancer; 2008 Apr;50(4):784-7
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years.
  • BACKGROUND: Peripheral T-cell lymphomas (PTCL) are very rare in children and this has prevented assessment of best treatment and prognosis.
  • Anaplastic large cell lymphoma and mycosis fungoides were excluded due to recent publications describing UK experience with these disorders.
  • RESULTS: Twenty-five cases were identified, comprising 1.6% of non-Hodgkin lymphoma (NHL) registrations; 17 (68%) children with PTCL-unspecified (PTCL-u), 3 (12%) with angiocentric PTCL, 3 (12%) with angioimmunoblastic PTCL, and 2 (8%) with subcutaneous panniculitis-like T-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18022899.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Martinez-Delgado B: Peripheral T-cell lymphoma gene expression profiles. Hematol Oncol; 2006 Sep;24(3):113-9
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma gene expression profiles.
  • Peripheral T-cell lymphomas (PTCL) constitute an heterogeneous group of tumours with different morphologic, immunophenotypic, and clinical characteristics.
  • Different molecular subgroups within PTCL unspecified have been identified associated to different expression profiles.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Leukemic. Lymphoma, T-Cell, Peripheral / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Cell Differentiation / genetics. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 John Wiley & Sons, Ltd.
  • (PMID = 16676369.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 35
  •  go-up   go-down


35. Tomita N, Motomura S, Hyo R, Takasaki H, Takemura S, Taguchi J, Fujisawa S, Ogawa K, Ishigatsubo Y, Takeuchi K: Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma. Cancer; 2007 Mar 15;109(6):1146-51
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
  • BACKGROUND: Peripheral T-cell lymphomas (PTCLs) are a biologically heterogeneous subgroup of lymphomas with poor prognosis.
  • In this study, the authors analyzed the clinical behaviors of PTCLs and diffuse large B-cell lymphoma (DLBCL).
  • METHODS: The authors compared the characteristics and outcomes of 59 patients with PTCLs, including 33 angioimmunoblastic T-cell lymphomas and 26 unspecified peripheral T-cell lymphomas, with the characteristics and outcomes of 193 patients with DLBCLs who were treated in the era before rituximab.
  • T-cell phenotype itself did not appear to have a significant impact on either response or survival.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / mortality


36. Struski S, Leymarie V, Helias C, Falkenrodt A, Fohrer C, Audhuy B, Lioure B, Moskovtchenko P, Mazurier I, Galoisy AC, Gervais C, Mauvieux L, Herbrecht R, Bergerat JP, Lessard M: [A cytological, immunophenotypical and cytogenetical study of 136 consecutive cases of B-cell chronic lymphoid hemopathies]. Pathol Biol (Paris); 2007 Feb;55(1):59-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A cytological, immunophenotypical and cytogenetical study of 136 consecutive cases of B-cell chronic lymphoid hemopathies].
  • [Transliterated title] Etude cytologique, immunophénotypique et cytogénétique d'une série de 136 cas consécutifs d'hémopathies lymphoïdes chroniques à cellules B matures.
  • A cytological, immunophenotypical and cytogenetical study of 136 chronic B-cell proliferations (93 CLL, 43 B-cell lymphomas) was led in order to precise diagnosis and to characterize and appreciate chromosomal rearrangements.
  • In this series, mainly selected on blood lymphocytosis criteria, B-CLL were twice more frequent than small B-cell lymphomas.
  • The frequency of clonal abnormalities (CC and FISH) was 74.8% for this series, with 74.4% for lymphomas and 75.3% for CLL, mainly of Binet stage A (69 A, 13 B, 1 C, 10 unspecified).
  • In CLL, 13q14 cryptic deletions and translocations were widely majority, 14q32 translocations and trisomy 12 being predominant in lymphoma series.
  • Interphase FISH study of non-clonal metaphasic abnormalities with locus-specific probes often revealed unrecognised clones.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, B-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690228.001).
  • [ISSN] 0369-8114
  • [Journal-full-title] Pathologie-biologie
  • [ISO-abbreviation] Pathol. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


37. Piccaluga PP, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S, Went P, Klein U, Zinzani PL, Baccarani M, Dalla Favera R, Pileri SA: Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest; 2007 Mar;117(3):823-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets.
  • Peripheral T cell lymphoma, unspecified (PTCL/U), the most common form of PTCL, displays heterogeneous morphology and phenotype, poor response to treatment, and poor prognosis.
  • Comparison with the profiles of purified T cell subpopulations (CD4+, CD8+, resting [HLA-DR-], and activated [HLA-DR+]) reveals that PTCLs/U are most closely related to activated peripheral T lymphocytes, either CD4+ or CD8+.
  • When compared with normal T cells, PTCLs/U display deregulation of functional programs often involved in tumorigenesis (e.g., apoptosis, proliferation, cell adhesion, and matrix remodeling).
  • [MeSH-major] Gene Expression. Gene Expression Profiling. Lymphoma, T-Cell, Peripheral / genetics. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Adult. Aged. Apoptosis / genetics. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cell Adhesion / genetics. Female. HLA-DR Antigens / analysis. Humans. Lymphocyte Activation. Male. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2002 Dec 12;21(57):8696-704 [12483522.001]
  • [Cites] Oncogene. 2003 Jan 23;22(3):343-50 [12545155.001]
  • [Cites] Blood. 2003 May 1;101(9):3391-7 [12506022.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25808-15 [12736251.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1042-50 [12689942.001]
  • [Cites] Eur J Biochem. 2003 Aug;270(16):3408-21 [12899698.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):24015-23 [15044484.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 6):12-7 [15175999.001]
  • [Cites] Hematol J. 2004;5 Suppl 3:S133-7 [15190295.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):68-78 [15210760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9740-4 [15210942.001]
  • [Cites] Int Immunol. 2004 Aug;16(8):1109-24 [15210650.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4971-82 [15297397.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1931-9 [15166033.001]
  • [Cites] Hum Pathol. 1983 Sep;14(9):745-72 [6350154.001]
  • [Cites] Blood. 1999 May 15;93(10):3487-93 [10233901.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1283-316 [10508235.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):849-56 [15499612.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):306-14 [15671560.001]
  • [Cites] Mol Endocrinol. 2005 Feb;19(2):527-39 [15486044.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1897-903 [15753388.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2254-63 [16270046.001]
  • [Cites] J Immunol. 2005 Dec 15;175(12):7837-47 [16339519.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1867-79 [16373702.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1255-64 [16210342.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1560-70 [16288225.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1174-82 [16675713.001]
  • [Cites] Adv Exp Med Biol. 2003;532:141-51 [12908555.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):33801-8 [12826661.001]
  • [Cites] Genome Biol. 2003;4(10):R70 [14519205.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7762-73 [14586402.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Curr Opin Hematol. 2004 Jan;11(1):51-7 [14676627.001]
  • [Cites] J Exp Med. 2004 Jan 5;199(1):59-68 [14707115.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):146-53 [14743220.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):935-42 [14990650.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2072-81 [15041728.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2879-91 [15070659.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1837-48 [15111330.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2217-28 [15161654.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Feb;117(1):71-9 [10700871.001]
  • [Cites] J Histochem Cytochem. 2000 Jun;48(6):747-54 [10820148.001]
  • [Cites] Bioinformatics. 2000 Apr;16(4):341-57 [10869032.001]
  • [Cites] J Clin Pathol. 1987 Sep;40(9):995-1015 [3312308.001]
  • [Cites] J Clin Pathol. 1989 Apr;42(4):398-402 [2469701.001]
  • [Cites] Hematol Pathol. 1992;6(3):131-41 [1429341.001]
  • [Cites] Br J Haematol. 1993 Jun;84(2):346-8 [8398842.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):46-55 [7856738.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6380-5 [9177226.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):583-92 [9261528.001]
  • [Cites] J Pathol. 1997 Sep;183(1):116-23 [9370957.001]
  • [Cites] J Biochem. 1998 May;123(5):767-76 [9562604.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] J Clin Pathol. 1998 Jul;51(7):506-11 [9797726.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Proc Int Conf Intell Syst Mol Biol. 2000;8:75-85 [10977068.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):438-47 [10989645.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1147-54 [11021819.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5603-7 [11059746.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11414-9 [11150309.001]
  • [Cites] Nat Genet. 2001 May;28(1):21-8 [11326270.001]
  • [Cites] J Biol Chem. 2001 Jan 26;276(4):2802-7 [11060313.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 1;128(1):1-6 [11454421.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 Nov;281(5):C1524-32 [11600415.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2865-8 [11675364.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19922-8 [11891225.001]
  • [Cites] Cytokine. 2002 Mar 21;17(6):324-34 [12061840.001]
  • [Cites] Oncogene. 2002 Jun 27;21(28):4462-70 [12080476.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):454-60 [12216074.001]
  • [Cites] Oncogene. 2002 Nov 21;21(53):8178-85 [12444554.001]
  • [Cites] Ann Clin Lab Sci. 2002 Fall;32(4):339-51 [12458885.001]
  • (PMID = 17304354.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-DR Antigens
  • [Other-IDs] NLM/ PMC1794115
  •  go-up   go-down


38. Nakagawa M, Nakagawa-Oshiro A, Karnan S, Tagawa H, Utsunomiya A, Nakamura S, Takeuchi I, Ohshima K, Seto M: Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia/lymphoma. Clin Cancer Res; 2009 Jan 1;15(1):30-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia/lymphoma.
  • PURPOSE: Peripheral T-cell lymphoma, unspecified (PTCL-U) comprises histopathologically and clinically heterogeneous groups.
  • Moreover, we compared the genetic, histopathologic, and prognostic features of the PTCL-U cases with those of 59 cases of lymphoma-type adult T-cell leukemia/lymphoma (ATLL).
  • PTCL-U cases with genomic imbalance showed distinct histopathologic and prognostic features compared with such cases without alteration and a marked genetic, histopathologic, and prognostic resemblance to lymphoma-type ATLL.
  • In addition to histopathologic similarity, the strong genetic and prognostic resemblance between PTCL-U cases with genomic imbalance detected by array CGH and lymphoma-type ATLL seems to support the notion that the former may constitute a distinct PTCL-U subgroup.
  • [MeSH-major] Chromosome Aberrations. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19118030.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Sabattini E, Pileri S, Baccarani M: Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol; 2007 Sep 20;25(27):4293-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
  • PURPOSE: To determine the antitumor activity of the proteasome inhibitor bortezomib in patients with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma unspecified (PTCLU) with isolated skin involvement.
  • CONCLUSION: This study suggests that bortezomib was well tolerated and has significant single-agent activity in patients with cutaneous T-cell lymphoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Boronic Acids / administration & dosage. Lymphoma, T-Cell / drug therapy. Mycosis Fungoides / drug therapy. Protease Inhibitors / pharmacology. Pyrazines / administration & dosage. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709797.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


40. Smith SD, Bolwell BJ, Rybicki LA, Brown S, Dean R, Kalaycio M, Sobecks R, Andresen S, Hsi ED, Pohlman B, Sweetenham JW: Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant; 2007 Aug;40(3):239-43
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen.
  • The role of high-dose therapy and autologous stem cell transplantation (ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined.
  • Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL.
  • Some retrospective studies have found comparable survival rates for patients with T- and B-cell NHL.
  • Thirty-two patients with PTCL-unspecified (PTCL-u; 11 patients) and anaplastic large-cell lymphoma (21 patients) underwent autologous stem cell transplant, mostly for relapsed or refractory disease.
  • These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T-cell lymphoma are needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / therapy. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Aged. Busulfan / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / therapy. Male. Middle Aged. Retrospective Studies. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17530000.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


41. Zheng YY, Chen G, Zhou XG, Zhang SH, Zhang YN: [Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):173-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma].
  • OBJECTIVE: To study the morphologic and immunophenotypic features of angioimmunoblastic T-cell lymphoma (AITL), as well as the origin of the proliferative follicular dendritic cells (FDCs) in AITL.
  • Cases of peripheral T-cell lymphoma, unspecified, extranodal NK/T-cell lymphoma, nasal-type, enteropathy-type T-cell lymphoma, anaplastic large cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma and reactive lymphoid proliferation were selected as controls.
  • RESULTS: Amongst the 29 cases of AITL studied, 75.9% (22/29) showed aberrant expression of CD10, while all except one of the controlled cases were negative, 82.8% (24/29) of the AITL cases expressed CXCL13, while all cases of peripheral T-cell lymphoma, unspecified were negative.
  • As for bcl-6 staining, although the highest percentage of bcl-6-positive cells was observed in AITL, the expression pattern was not useful in differentiating AITL from peripheral T-cell lymphoma, unspecified and lymphoid reaction.
  • Two of the cases, which contained obvious germinal centers, had the follicular dendritic cell meshwork extending beyond the lymphoid follicles.
  • [MeSH-major] Chemokine CXCL13 / metabolism. Dendritic Cells, Follicular / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neprilysin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575853.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


42. Summers TA Jr, Rush W, Aguilera N, Lupton G: Cutaneous involvement in the lymphoepithelioid variant of peripheral T-cell lymphoma, unspecified (Lennert lymphoma). Report of a case and review of the literature. J Cutan Pathol; 2009 Oct;36 Suppl 1:25-30
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous involvement in the lymphoepithelioid variant of peripheral T-cell lymphoma, unspecified (Lennert lymphoma). Report of a case and review of the literature.
  • Lennert lymphoma (LL), or the lymphoepithelioid variant of peripheral T-cell lymphoma, is an uncommon entity with rarely seen or reported presentations in the skin.
  • Cutaneous involvement of LL has been characterized by asymptomatic, non-ulcerated, red to violet papules, nodules and small plaques (less than 5 cm) on the trunk and extremities.
  • Immunophenotyping shows a dense monoclonal T-cell population commonly associated with aberrant loss of T-cell-associated antigens.
  • T-cell receptor gene rearrangements are also identified.
  • Herein, we present a case of cutaneous involvement by LL at the time of initial presentation that persisted after initiation of chemotherapy and was finally verified as secondary cutaneous involvement of LL 1 year later histologically, immunophenotypically and by T-cell receptor gene rearrangement studies.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology. Skin Neoplasms / pathology. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19775391.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  • [Number-of-references] 18
  •  go-up   go-down


43. Futagami A, Aoki M, Kawana S: A case of peripheral T-cell lymphoma unspecified involving subcutaneous tissue. Leuk Lymphoma; 2005 May;46(5):785-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of peripheral T-cell lymphoma unspecified involving subcutaneous tissue.
  • Immunohistochemical studies revealed a post-thymic T-cell phenotype.
  • A genetic analysis demonstrated a rearrangement of the T-cell receptor chain gene.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / diagnosis. Neoplasm Regression, Spontaneous. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019520.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Dupuis J, Emile JF, Mounier N, Gisselbrecht C, Martin-Garcia N, Petrella T, Bouabdallah R, Berger F, Delmer A, Coiffier B, Reyes F, Gaulard P, Groupe d'Etude des Lymphomes de l'Adulte (GELA): Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood; 2006 Dec 15;108(13):4163-9
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study.
  • Peripheral T-cell lymphomas (PTCLs) are rare and have a dismal prognosis.
  • The most frequent subtype is PTCL, unspecified.
  • Lymph node samples from 110 patients with PTCL, unspecified included in LNH87 and LNH93 trials were available.
  • [MeSH-major] Epstein-Barr Virus Infections / mortality. Herpesvirus 4, Human. Lymphoma, T-Cell, Peripheral / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16902151.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


45. Yang DH, Kim WS, Kim SJ, Bae SH, Kim SH, Kim IH, Yoon SS, Mun YC, Shin HJ, Chae YS, Kwak JY, Kim H, Kim MK, Kim JS, Won JH, Lee JJ, Suh CW: Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant; 2009 Jan;15(1):118-25
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome.
  • High-dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) offers a rescue option for T cell lymphoma patients with poor prognosis.
  • However, the effectiveness of HDT/ASCT in patients with various peripheral T cell subtypes, optimal transplant timing, and the prognostic factors that predict better outcomes, have not been identified.
  • We retrospectively investigated the clinical outcomes and prognostic factors for HDT/ASCT in 64 Korean patients with peripheral T cell lymphoma, unspecified (PTCL-U) between March 1995 and February 2007.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, T-Cell, Peripheral / therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135950.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Avilés A, Castañeda C, Neri N, Cleto S, Talavera A, González M, Huerta-Guzmán J, Nambo MJ: Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified. Med Oncol; 2008;25(3):360-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified.
  • We performed a controlled clinical trial to define the use of a brief therapy: CMED (cyclophosphamide, etoposide, methotrexate, and dexamethasone) compared with standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of peripheral T-cell lymphoma unspecific (PTCLu).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2296-301 [9196143.001]
  • [Cites] Br J Haematol. 2005 May;129(3):366-72 [15842660.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1255-64 [16210342.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]
  • [Cites] Cancer. 2005 May 15;103(10):2091-8 [15816054.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2261-7 [15512815.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1385-9 [15359637.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1426-31 [1712837.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4514-20 [9192775.001]
  • [Cites] Histopathology. 2003 Nov;43(5):462-9 [14636272.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):652-7 [17229774.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1601-8 [15378507.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1790-7 [15550584.001]
  • [Cites] Med Oncol. 2003;20(1):13-7 [12665679.001]
  • [Cites] Br J Cancer. 2001 Nov 16;85(10):1425-31 [11720423.001]
  • (PMID = 18247163.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; CMED protocol
  •  go-up   go-down


47. Ferrer G, Gutierrez G, Schwartz AM, Delaney MD: Peripheral T-cell lymphoma with endobronchial involvement. J Bronchology Interv Pulmonol; 2010 Apr;17(2):169-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma with endobronchial involvement.
  • Peripheral T-cell lymphoma unspecified (PTCL-U) is a lymphoproliferative disorder characterized by localized malignant T-lymphocyte infiltration of the skin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23168739.001).
  • [ISSN] 1944-6586
  • [Journal-full-title] Journal of bronchology & interventional pulmonology
  • [ISO-abbreviation] J Bronchology Interv Pulmonol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Chen JH, Chan DC, Lee HS, Liu HD, Hsieh CB, Yu JC, Liu YC, Chen CJ: Spontaneous splenic rupture associated with hepatosplenic gammadelta T-cell lymphoma. J Formos Med Assoc; 2005 Aug;104(8):593-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous splenic rupture associated with hepatosplenic gammadelta T-cell lymphoma.
  • It has been reported in patients with acute and chronic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, and histiocytic lymphoma.
  • The clinicopathologic features suggested a hepatosplenic gammadelta T-cell lymphoma (HSgammadeltaTL).
  • Here, we report a rare case of spontaneous splenic rupture associated with HSgammadeltaTL, unspecified in the World Health Organization classification.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193182.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


49. Weaver J, Mahindra AK, Pohlman B, Jin T, Hsi ED: Non-mycosis fungoides cutaneous T-cell lymphoma: reclassification according to the WHO-EORTC classification. J Cutan Pathol; 2010 May;37(5):516-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-mycosis fungoides cutaneous T-cell lymphoma: reclassification according to the WHO-EORTC classification.
  • BACKGROUND: Non-mycosis fungoides (non-MF) primary cutaneous T-cell lymphomas (PCTCL) are heterogeneous and divided into subgroups by the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification of cutaneous lymphomas.
  • METHODS: Forty-four non-MF PCTCL cases with available tissue for phenotyping, adequate clinical staging information and follow-up were reclassified according to the WHO-EORTC classification.
  • RESULTS: Non-MF PCTCL had a longer overall survival (OS) (13.8 years) compared with secondary cutaneous T-cell lymphoma (SC-TCL) (2.5 years).
  • Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) had the most favorable outcome (OS 14.1 years), whereas secondary and primary peripheral T-cell lymphoma, unspecified had the shortest OS (2.5 and 2.4 years, respectively).
  • Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma (CTLCD4) appeared to have a favorable course.
  • CONCLUSIONS: Most non-MF PCTCL can be classified according to the WHO-EORTC classification.
  • Non-MF PCTCL is a heterogeneous group with a favorable outcome compared to SC-TCL, especially PC-ALCL and CTLCD4.
  • Separation of non-MF PCTCL into indolent and aggressive groups appears clinically significant and may provide direction for therapeutic decisions.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / classification. Skin Neoplasms / classification


50. Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S, Gazzola A, Gloghini A, Righi S, Rossi M, Tagliafico E, Zinzani PL, Zupo S, Baccarani M, Pileri SA: Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res; 2007 Nov 15;67(22):10703-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation.
  • Angioimmunoblastic lymphoma (AILT) is the second most common subtype of peripheral T-cell lymphoma (PTCL) and is characterized by dismal prognosis.
  • We performed gene expression profile (GEP) analysis of six AILT, six anaplastic large cell lymphomas (ALCL), 28 PTCL-unspecified (PTCL/U), and 20 samples of normal T lymphocytes (including CD4(+), CD8(+), and activated and resting subpopulations), aiming to (a) assess the relationship of AILT with other PTCLs, (b) establish the relationship between AILT and normal T-cell subsets, and (c) recognize the cellular programs deregulated in AILT possibly looking for novel potential therapeutic targets.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Lymphoma / genetics. Lymphoma / metabolism. Lymphoma, T-Cell, Peripheral / metabolism. NF-kappa B / metabolism. Proto-Oncogene Proteins c-rel / biosynthesis. T-Lymphocytes, Helper-Inducer / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006812.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-rel; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


51. Chen SW, Chang ST, Lu CL, Hwang WS, Tsao CJ, Huang WT, Chang KY, Chuang SS: Upper aerodigestive tract lymphoma in Taiwan. J Clin Pathol; 2010 Oct;63(10):888-93
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper aerodigestive tract lymphoma in Taiwan.
  • AIM: To better understand the spectrum of primary lymphomas in the upper aerodigestive tract, a common site of extranodal lymphoma.
  • MATERIALS AND METHODS: Lymphoma cases diagnosed at an institution in southern Taiwan from 1992 to 2007 were retrospectively studied with pathology and history review, immunohistochemistry, in situ hybridisation for Epstein-Barr virus (EBER-ISH), and statistical analysis.
  • Phenotypically, there were 45 (64%) B cell and 25 (36%) T cell or extranodal natural killer (NK)/T cell lymphoma (ENKL) including 42 (60%) diffuse large B cell lymphomas (DLBCLs), 22 (31%) ENKLs, three unspecified peripheral T cell lymphomas, two follicular lymphomas and one Burkitt lymphoma.
  • The 5-year overall survival for all patients was 56.3% with B and T or NK/T cell lymphomas at 66.0% and 40.6%, respectively.
  • Univariate analysis revealed that sinonasal presentation, T or NK/T cell phenotype, raised lactate dehydrogenase (LDH) activity, and Ann Arbor stage III/IV diseases were associated with prognostically significant higher hazard ratio (HR) of lymphoma-related death.
  • CONCLUSIONS: Only a limited number of lymphoma entities occurred primarily in this anatomical region.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Child. Epidemiologic Methods. Epstein-Barr Virus Infections / complications. Female. Humans. L-Lactate Dehydrogenase / blood. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Lymphoma, B-Cell / virology. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / therapy. Lymphoma, T-Cell / virology. Male. Middle Aged. Mouth Neoplasms / pathology. Mouth Neoplasms / therapy. Mouth Neoplasms / virology. Neoplasm Staging. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876320.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


52. Konstantinou K, Yamamoto K, Ishibashi F, Mizoguchi Y, Kurata M, Nakagawa Y, Suzuki K, Sawabe M, Ohta M, Miyakoshi S, Crawley JT, Kitagawa M: Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma. Br J Haematol; 2009 Mar;144(5):696-704
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AILT) is a malignant disease of peripheral T-cell origin that is characterized by a prominent proliferation of high endothelial venules in the lymph node.
  • To investigate angiogenic mechanisms in AILT we measured the angiogenic mediator gene expression levels in the lymph nodes of 54 non-Hodgkin lymphoma patients, by immunostaining and quantitative reverse transcription polymerase chain reaction.
  • Angiogenic mediators angiopoietin (Ang) 1 (ANGPT1), Ang2 (ANGPT2) and their receptor, Tie2 (TEK), vascular endothelial growth factor (VEGF; VEGFA) and its receptor, VEGFR2 (KDR), and hepatocyte growth factor (HGF) and its receptor, c-Met (MET) were all more highly expressed in AILT lymph nodes (16 cases) than in B-cell lymphomas (24 cases).
  • Moreover, significantly higher Ang1 and Tie2 expression was detected in AILT cases with CD10-positive neoplastic T-cells by comparison with unspecified peripheral T-cell lymphoma (14 cases).
  • [MeSH-major] Angiopoietins / metabolism. Lymph Nodes / metabolism. Lymphoma, T-Cell, Peripheral / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19120365.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiopoietin-1; 0 / Angiopoietin-2; 0 / Angiopoietins; 0 / Antigens, CD3; 0 / Biomarkers, Tumor; 0 / Receptors, Complement 3d; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, TIE-2; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


53. Ko OB, Lee DH, Kim SW, Lee JS, Kim S, Huh J, Suh C: Clinicopathologic characteristics of T-cell non-Hodgkin's lymphoma: a single institution experience. Korean J Intern Med; 2009 Jun;24(2):128-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics of T-cell non-Hodgkin's lymphoma: a single institution experience.
  • BACKGROUND/AIMS: Although the incidence of T-cell non-Hodgkin's lymphoma (NHL) is higher in Far East Asia than in Western countries, its incidence and clinical course in Korea are not well-defined.
  • Therefore, we assessed the relative frequency and clinical features of T-cell NHL in Korea.
  • RESULTS: 101 (17.2%) had T-cell NHL.
  • The most frequent subtypes of T-cell NHL were extranodal NK/T-cell lymphoma, nasal type (NASAL), peripheral T-cell lymphoma, unspecified type (PTCL-U), and anaplastic large cell lymphoma, T/null cell, primary systemic type (ALCL).
  • CONCLUSIONS: The relative frequency of T-cell NHL seems to be decreasing in Korea, although NASAL remains frequent.
  • Large-scale studies are warranted for Korean patients with T-cell NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Oct;5(5):983-1001 [1938764.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):923-30 [9378552.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2439-48 [9635538.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):806-12 [9708949.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):1-12 [15480663.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2797-804 [15728226.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1255-64 [16210342.001]
  • [Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Sep;15(3):533-47 [12468404.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Hum Pathol. 1983 Sep;14(9):745-72 [6350154.001]
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):143-8 [6381328.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Apr;21(4):487-92 [4007017.001]
  • [Cites] Jpn J Clin Oncol. 1985 Sep;15(3):517-35 [2997510.001]
  • [Cites] Jpn J Clin Oncol. 1985 Dec;15(4):645-51 [4094097.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):370-80 [8001008.001]
  • (PMID = 19543491.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2698621
  • [Keywords] NOTNLM ; Lymphoma / Peripheral / T-cell
  •  go-up   go-down


54. Feldman AL, Law M, Remstein ED, Macon WR, Erickson LA, Grogg KL, Kurtin PJ, Dogan A: Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia; 2009 Mar;23(3):574-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.
  • In contrast to myeloid and B-cell neoplasms, translocations in peripheral T-cell lymphomas (PTCLs) are poorly understood.
  • IRF4 translocations exist in myeloma and some B-cell lymphomas, but have not been reported earlier in PTCLs.
  • Two cases with t(6;14)(p25;q11.2) had translocations between IRF4 and the T-cell receptor-alpha (TCRA) locus.
  • Both were cytotoxic PTCLs, unspecified (PTCL-Us) involving bone marrow and skin.
  • In total, 8 of the remaining 10 cases were cutaneous anaplastic large-cell lymphomas (ALCLs) without TCRA rearrangements (57% of cutaneous ALCLs tested).
  • Detecting these translocations may be useful in lymphoma diagnosis.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] Genet Med. 2006 Jan;8(1):16-23 [16418595.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3653-61 [10845893.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):219-28 [11266530.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):686-94 [11455001.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Aug;129(1):1-9 [11520558.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1967-72 [12057901.001]
  • [Cites] Leukemia. 2006 Feb;20(2):313-8 [16341044.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):124-32 [17387297.001]
  • [Cites] J Pathol. 2007 Sep;213(1):99-105 [17582237.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Nov;46(11):1011-8 [17696193.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4293-7 [17709797.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2259-67 [17519389.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2332-43 [17625604.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):516-26 [18275429.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2516-20 [17975015.001]
  • [Cites] Hum Pathol. 2008 Apr;39(4):557-63 [18234282.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3867-71 [18235046.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):455-63 [18223553.001]
  • [Cites] Med Res Rev. 2008 May;28(3):372-412 [17694547.001]
  • [Cites] Br J Dermatol. 2008 Jun;158(6):1280-7 [18410414.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1268-72 [17989713.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1139-43 [18401419.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):178-85 [18628085.001]
  • [Cites] Histopathology. 2000 Feb;36(2):136-44 [10672058.001]
  • [Cites] Leukemia. 2000 Mar;14(3):449-56 [10720141.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):773-9 [12428799.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jun;37(2):176-85 [12696066.001]
  • [Cites] Histopathology. 2003 Nov;43(5):462-9 [14636272.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Leuk Res. 1985;9(9):1139-48 [3877852.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):226-30 [9326949.001]
  • [Cites] J Invest Dermatol. 1997 Nov;109(5):636-40 [9347791.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2076-84 [9490693.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jun;22(2):114-21 [9598798.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):228-36 [10029454.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2949-51 [10077617.001]
  • [Cites] Am J Clin Pathol. 1999 Sep;112(3):319-29 [10478136.001]
  • [Cites] Leukemia. 2005 Jan;19(1):77-82 [15510210.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3058-65 [15626743.001]
  • [Cites] Hum Pathol. 2005 May;36(5):494-504 [15948116.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):421-9 [16191511.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2247-53 [16193085.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:131-5 [10707795.001]
  • (PMID = 18987657.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / P50 CA097274-07; United States / NCI NIH HHS / CA / P50 CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / interferon regulatory factor-4
  • [Other-IDs] NLM/ NIHMS70248; NLM/ PMC2656414
  •  go-up   go-down


55. Weisel KC, Weidmann E, Anagnostopoulos I, Kanz L, Pezzutto A, Subklewe M: Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma. Int J Hematol; 2008 Nov;88(4):434-40
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma.
  • Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders occur at an increasing frequency in various hereditary and acquired states of immune dysfunction.
  • In a few cases of T-cell lymphoma, especially in angioimmunoblastic T-cell lymphoma (AILT), EBV-associated B-cell lymphoproliferative disorders have been reported.
  • Here, we present two cases of EBV-associated B-cell lymphoma after treatment of T-cell lymphoma (AILT and peripheral T-cell lymphoma, unspecified, PTCL-NOS) with a regimen containing alemtuzumab and fludarabine.
  • Conventional and immunohistological tissue staining showed the typical features of highly proliferating diffuse large B-cell lymphoma in both cases.
  • The monoclonal B-cell population displayed EBV latency type III.
  • At the time of diagnosis the cellular immune status of both patients was severely compromised with an absolute CD4 T-cell count below <120 microl(-1).
  • Our observation supports the notion that combination of cytotoxic drugs and immunosuppressive antibodies in patients with T-cell lymphoma may severely aggravate the already present immunodeficiency.
  • We suggest to monitor the cellular immune status in combination with the EBV load in high risk patients for early detection-and possibly intervention-of EBV-associated lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell / pathology. Neoplasms, Second Primary / drug therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4267-72 [12543862.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Clin Infect Dis. 2006 Jul 1;43(1):16-24 [16758413.001]
  • [Cites] Annu Rev Immunol. 1997;15:405-31 [9143694.001]
  • [Cites] Clin Infect Dis. 2007 Jan 15;44(2):204-12 [17173218.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3891-7 [12228210.001]
  • [Cites] Transplantation. 2005 Oct 15;80(2 Suppl):S254-64 [16251858.001]
  • [Cites] Blood. 2002 Aug 1;100(3):768-73 [12130484.001]
  • [Cites] Leukemia. 2004 Mar;18(3):484-90 [14749699.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):87-91 [15982349.001]
  • [Cites] Haematologica. 2004 Oct;89(10):1248-52 [15477211.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2570-2; discussion 2570-2 [14695424.001]
  • [Cites] Cancer. 1987 Nov 15;60(10):2412-8 [2822218.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):267-284 [6998005.001]
  • [Cites] Transpl Immunol. 2007 Apr;17(3):203-10 [17331848.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4059-66 [12829591.001]
  • [Cites] Blood. 2004 May 15;103(10):3979-81 [14751931.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):630-6 [11979093.001]
  • [Cites] Ann Intern Med. 1992 Sep 1;117(5):364-70 [1380221.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1039-41 [18502831.001]
  • [Cites] Br J Haematol. 2006 Jan;132(1):3-12 [16371014.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1502-5 [10666232.001]
  • [Cites] Leuk Res. 1991;15(9):837-46 [1656151.001]
  • [Cites] Histopathology. 2005 Apr;46(4):464-6 [15810960.001]
  • [Cites] Arch Pathol Lab Med. 2006 Nov;130(11):1707-11 [17076535.001]
  • [Cites] Br J Haematol. 2007 Sep;138(6):733-9 [17672882.001]
  • [Cites] Am J Transplant. 2007 Jun;7(6):1648-55 [17511690.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1804-12 [1327284.001]
  • [Cites] Haematologica. 2008 Feb;93(2):e30-1 [18245646.001]
  • [Cites] Am J Transplant. 2007 Nov;7(11):2619-25 [17868060.001]
  • [Cites] Clin Lymphoma. 2002 Sep;3(2):105-10 [12435283.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:113-6 [10707791.001]
  • [Cites] Semin Hematol. 2006 Apr;43(2 Suppl 2):S27-34 [16549112.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5748-55 [16115912.001]
  • (PMID = 18839273.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 04079A1RDZ / Cytarabine; 3A189DH42V / alemtuzumab
  •  go-up   go-down


56. Sung CO, Ko YH, Park S, Kim K, Kim W: Immunoreactivity of CD99 in non-Hodgkin's lymphoma: unexpected frequent expression in ALK-positive anaplastic large cell lymphoma. J Korean Med Sci; 2005 Dec;20(6):952-6
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity of CD99 in non-Hodgkin's lymphoma: unexpected frequent expression in ALK-positive anaplastic large cell lymphoma.
  • To verify the spectrum of CD99-expressing lymphoid malignancy, an immunohistochemical study for CD99 was carried out in 182 cases of non-Hodgkin's lymphoma, including 21 lymphoblastic lymphomas, 11 small lymphocytic lymphomas, 9 mantle cell lymphomas, 12 follicular lymphomas, 37 diffuse large B cell lymphomas, 18 Burkitt's lymphomas, 28 NK/T-cell lymphomas, 8 angioimmunoblastic T-cell lymphomas, 23 peripheral T-cell lymphomas, unspecified, and 15 systemic anaplastic large cell lymphomas.
  • Majority of T and NK cell lymphomas were negative for CD99, except anaplastic large cell lymphomas (ALCLs).
  • Of the mature B-cell lymphomas, 5.4% (2/37) of diffuse large B cell lymphomas and 11.1% (2/18) of Burkitt's lymphomas expressed CD99.
  • In conclusion, CD99 is infrequently expressed in mature B and T cell lymphomas, except ALK-positive ALCL.
  • [MeSH-major] Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Non-Hodgkin / immunology. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:33-8 [1646624.001]
  • [Cites] Am J Pathol. 1990 Nov;137(5):1047-57 [2173409.001]
  • [Cites] Histopathology. 1993 Dec;23(6):557-61 [8314240.001]
  • [Cites] Hum Pathol. 1994 Apr;25(4):396-9 [8163272.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):486-94 [7513503.001]
  • [Cites] Blood. 1996 May 15;87(10):4340-7 [8639794.001]
  • [Cites] Hum Pathol. 1996 Dec;27(12):1273-6 [8958297.001]
  • [Cites] Mod Pathol. 1997 Apr;10(4):277-82 [9110287.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2250-8 [9278313.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):769-73 [9720506.001]
  • [Cites] J Immunol. 1998 Nov 1;161(9):4671-8 [9794396.001]
  • [Cites] Br J Haematol. 1999 Jun;105(3):690-5 [10354133.001]
  • [Cites] J Korean Med Sci. 2005 Feb;20(1):50-5 [15716602.001]
  • [Cites] Mod Pathol. 2000 Apr;13(4):452-8 [10786814.001]
  • [Cites] Virchows Arch. 2000 Sep;437(3):270-4 [11037347.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):527-35 [11485911.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):587-94 [11697486.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4540-6 [12036886.001]
  • [Cites] J Korean Med Sci. 2002 Aug;17(4):483-9 [12172043.001]
  • [Cites] FEBS Lett. 2003 Nov 20;554(3):478-84 [14623115.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):353-64 [15093542.001]
  • [Cites] Oncogene. 2004 Jul 22;23(33):5664-74 [15184883.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6127-31 [2844401.001]
  • [Cites] Blood. 1994 Jan 15;83(2):415-25 [7506950.001]
  • (PMID = 16361803.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC2779325
  •  go-up   go-down


57. Medeiros LJ, Elenitoba-Johnson KS: Anaplastic Large Cell Lymphoma. Am J Clin Pathol; 2007 May;127(5):707-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic Large Cell Lymphoma.
  • Session 8 of the 2005 Society of Hematopathology/European Association for Haematopathology Workshop was devoted to anaplastic large cell lymphoma (ALCL).
  • Most cases submitted were anaplastic lymphoma kinase (ALK)+ ALCL highlighting unusual clinical settings, histologic variants, and variant translocation partners.
  • Cases submitted as ALK- ALCL emphasized the immunohistochemical overlap with classical Hodgkin lymphoma (eg, CD15+/CD30+).
  • Many expressed the opinion that ALK-ALCL is not a distinct entity at the immunophenotypic or genetic level and is better designated as peripheral T-cell lymphoma (PTCL), unspecified.
  • Others suggested that the histologic features of ALK-ALCL are distinctive nevertheless and that this diagnosis has meaning that is lost by designating these neoplasms as PTCL, unspecified.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / analysis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511113.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 40
  •  go-up   go-down


58. Gjerdrum LM, Woetmann A, Odum N, Burton CM, Rossen K, Skovgaard GL, Ryder LP, Ralfkiaer E: FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia; 2007 Dec;21(12):2512-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival.
  • In this study, skin biopsies from 86 patients with mycosis fungoides (MF) and cutaneous T-cell lymphoma (CTCL) unspecified were analysed for the expression of FOXP3 on tumour cells and tumour-infiltrating Tregs.
  • MF with early or infiltrated plaques had significantly higher numbers of FOXP3+ Tregs than CTCL unspecified or advanced MF with tumours or transformation to large cell lymphoma.
  • An analysis of all patients demonstrated that increasing numbers of FOXP3+ Tregs were associated with improved survival in both MF and CTCL unspecified.
  • [MeSH-major] Forkhead Transcription Factors / analysis. Lymphocytes, Tumor-Infiltrating / immunology. Lymphoma, T-Cell, Cutaneous / pathology. Mycosis Fungoides / pathology. Skin Neoplasms / pathology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Humans. Jurkat Cells / chemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Recombinant Fusion Proteins / analysis. Survival Analysis

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713545.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


59. Jun HJ, Kim WS, Yang JH, Yi SY, Ko YH, Lee J, Jung CW, Kang SW, Park K: Orbital infiltration as the first site of relapse of primary testicular T-cell lymphoma. Cancer Res Treat; 2007 Mar;39(1):40-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital infiltration as the first site of relapse of primary testicular T-cell lymphoma.
  • The pathologic diagnosis of the radical orchiectomy specimen was peripheral T-cell lymphoma, unspecified (PTCL-u).
  • Although the patient received intensive chemotherapy with autologous hematopoietic stem cell transplantation, he ultimately died of leptomeningeal seeding.
  • Because both the central nervous system (CNS) and the orbit are sanctuary sites for chemotherapy, orbital infiltration of lymphoma should prompt physicians to evaluate involvement of the CNS and to consider performing prophylactic intrathecal chemotherapy as a treatment option.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 1999 Nov;106(11):2109-20 [10571346.001]
  • [Cites] Eur J Cancer. 1994;30A(12):1760-4 [7880601.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):376-90 [8141430.001]
  • [Cites] Histopathology. 1989 Aug;15(2):147-56 [2777217.001]
  • [Cites] Br J Urol. 1984 Oct;56(5):525-30 [6398719.001]
  • [Cites] Arch Ophthalmol. 1984 Mar;102(3):399-402 [6608342.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):154-61 [10618618.001]
  • (PMID = 19746228.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2739356
  • [Keywords] NOTNLM ; Eye neoplasm / Non-Hodgkin's lymphoma / T cell lymphoma / Testes
  •  go-up   go-down


60. Ferry JA, Fung CY, Zukerberg L, Lucarelli MJ, Hasserjian RP, Preffer FI, Harris NL: Lymphoma of the ocular adnexa: A study of 353 cases. Am J Surg Pathol; 2007 Feb;31(2):170-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma of the ocular adnexa: A study of 353 cases.
  • We studied the cases of 353 patients with lymphoma involving the ocular adnexa diagnosed at the Massachusetts General Hospital between 1974 and 2005.
  • In 277 cases, there was no known history of lymphoma.
  • Seventy-six patients had a history of lymphoma, with the ocular adnexa being involved at relapse or with progression of the previously diagnosed lymphoma.
  • The patients had marginal zone lymphoma (182 cases), follicular lymphoma (80 cases), mantle cell lymphoma (18 cases), small lymphocytic lymphoma/chronic lymphocytic leukemia (13 cases), lymphoplasmacytic lymphoma (4 cases), splenic marginal zone lymphoma (2 cases), low-grade B cell, not subclassified (19 cases), precursor B lymphoblastic lymphoma (3 cases), diffuse large B-cell lymphoma (26 cases), and 1 case each of high-grade B-cell lymphoma, not subclassified, peripheral T-cell lymphoma, unspecified type, extranodal NK/T-cell lymphoma, nasal type, and Hodgkin lymphoma, nodular sclerosis type.
  • Almost all marginal zone lymphoma patients (168 of 182, 92%) had primary ocular adnexal lymphoma.
  • Fourteen marginal zone lymphoma patients (8%) had a prior history of lymphoma, usually arising in another extranodal site.
  • Twenty-five of 80 (31%) follicular lymphoma patients had a prior history of lymphoma, usually arising in lymph nodes.
  • Patients with mantle cell lymphoma, chronic lymphocytic leukemia, lymphoplasmacytic lymphoma, and splenic marginal zone lymphoma almost always had a prior history of lymphoma or were known to have widespread disease at the time of diagnosis of ocular adnexal lymphoma.
  • A subset of the diffuse large B-cell lymphomas were associated with large destructive masses involving adjacent structures such as paranasal sinuses, raising the possibility that they may have arisen from one of the adjacent structures and involved the ocular adnexa by direct extension.
  • The relatively high proportion of low-grade lymphoma, not subclassified, highlights the difficulty that may arise in distinguishing different types of low-grade lymphoma, particularly when biopsies are small and artifactually distorted.
  • Ocular adnexal lymphoma is primarily a disease of older adults, with a slight female preponderance.
  • Most lymphomas are low-grade B-cell lymphomas, with marginal zone lymphoma being by far the most common type.
  • Marginal zone lymphoma typically involves the ocular adnexa primarily, whereas other types of low-grade B-cell lymphoma often involve the ocular adnexa secondarily.
  • High-grade B-cell lymphomas only occasionally involve the ocular adnexa, and T-cell lymphoma, NK-cell lymphoma, and Hodgkin lymphoma are only rarely encountered in this site.
  • [MeSH-major] Conjunctival Neoplasms / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology. Lymphoma / pathology. Orbital Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255761.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


61. Notohamiprodjo M, Segerer S, Huss R, Hildebrandt B, Soler D, Djafarzadeh R, Buck W, Nelson PJ, von Luettichau I: CCR10 is expressed in cutaneous T-cell lymphoma. Int J Cancer; 2005 Jul 1;115(4):641-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCR10 is expressed in cutaneous T-cell lymphoma.
  • Cutaneous T-cell lymphoma (CTCL) is characterized by recruitment of malignant T-cell clones into the skin.
  • Here, we demonstrate extensive expression of CCR10 in skin biopsies of patients with Sezary syndrome (SS, n = 3), mycosis fungoides (MF, n = 2) and unspecified CTCL (n = 3).
  • The functionality of CCR10 and CXCR3 in SS was demonstrated using the SS T-cell line HUT78.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / genetics. Receptors, Chemokine / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Line, Tumor. Cell Movement. DNA Primers. Female. Humans. Immunohistochemistry. Jurkat Cells. Male. Middle Aged. RNA, Messenger / genetics. Receptors, CCR10. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15700309.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCR10 protein, human; 0 / DNA Primers; 0 / RNA, Messenger; 0 / Receptors, CCR10; 0 / Receptors, Chemokine
  •  go-up   go-down


62. Fragou M, Karakitsos D, Kalogeromitros A, Samonis G, Karabinis A: Peripheral T-cell lymphoma presenting as an ischemic stroke in a 23-year-old woman: a case report and review of the literature. J Med Case Rep; 2009;3:83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma presenting as an ischemic stroke in a 23-year-old woman: a case report and review of the literature.
  • INTRODUCTION: Peripheral T-cell lymphoma of the unspecified variant is a highly aggressive subtype of T-cell non-Hodgkin's lymphoma.
  • This is the first reported case of this type of lymphoma presenting as an ischemic stroke in a woman.
  • A biopsy of an enlarged inguinal lymph node of the patient, combined with an immunophenotypic analysis, revealed an unspecified variant of peripheral T-cell lymphoma.
  • CONCLUSION: Peripheral T-cell lymphoma of the unspecified variant is a highly aggressive subtype of peripheral T-cell lymphomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol. 2008 Mar;26(1):8-20 [18050364.001]
  • [Cites] Semin Oncol. 2006 Jun;33(3):342-7 [16769423.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1255-64 [16210342.001]
  • [Cites] Semin Neurol. 2004 Dec;24(4):453-60 [15637656.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Am J Pathol. 1985 Feb;118(2):316-24 [3155915.001]
  • [Cites] Hum Pathol. 1986 Jun;17(6):567-74 [3011639.001]
  • [Cites] Leuk Res. 2004 Dec;28(12):1287-92 [15475070.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1447-9 [15367401.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • (PMID = 19946559.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2783082
  •  go-up   go-down


63. Hotta T: Treatment of T-Cell lymphoma. Hematology; 2005;10 Suppl 1:193-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of T-Cell lymphoma.
  • T-cell lymphoma composes 25% of lymphoid malignancies in Japan.
  • Peripheral T-cell lymphoma (PTCL) unspecified and adult T-cell leukemia/lymphoma (ATLL) are major subtypes of T-cell lymphoma.
  • The Japan Clinical Oncology Group (JCOG) has conducted 7 clinical trials for aggressive non-Hodgkin's lymphoma (NHL) including T-cell lymphoma.
  • JCOG trials revealed that patients with ATLL had an extremely poor prognosis as compared with other peripheral T-cell lymphomas.
  • Considering the poor prognosis of aggressive ATLL patients, allogeneic stem cell transplantation seems to be another promising approach for a cure of the disease.
  • [MeSH-major] Lymphoma, T-Cell / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Hematopoietic Stem Cell Transplantation. Humans. Japan

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16188671.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 19
  •  go-up   go-down


64. de Leval L, Rickman DS, Thielen C, Reynies Ad, Huang YL, Delsol G, Lamant L, Leroy K, Brière J, Molina T, Berger F, Gisselbrecht C, Xerri L, Gaulard P: The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood; 2007 Jun 1;109(11):4952-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.
  • The molecular alterations underlying the pathogenesis of angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma, unspecified (PTCL-u) are largely unknown.
  • The molecular profile of AITLs was characterized by a strong microenvironment imprint (overexpression of B-cell- and follicular dendritic cell-related genes, chemokines, and genes related to extracellular matrix and vascular biology), and overexpression of several genes characteristic of normal follicular helper T (T(FH)) cells (CXCL13, BCL6, PDCD1, CD40L, NFATC1).
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Lymphoma, T-Cell, Peripheral / immunology. Lymphoma, T-Cell, Peripheral / metabolism


65. Tong H, Ren Y, Qian W, Xiao F, Mai W, Meng H, Jin J: Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China. Int J Hematol; 2009 Oct;90(3):303-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China.
  • We reviewed 173 patients with an initial diagnosis of peripheral T-cell non-Hodgkin lymphoma (PTCL) and compared the patients with bone marrow involvement (BMI) to those without to have a better understanding of the clinical characteristics, treatments, survival and prognosis of PTCLs with BMI.
  • We found that 40% (70/173) of the patients had BMI, and its frequency was 64% in angioimmunoblastic T-cell lymphoma (TCL), 46% in PTCL unspecified, 29% in anaplastic large T-cell lymphoma, 23% in extranodal NK/T-cell lymphoma and 13% in enteropathy-type TCL.
  • In the BMI group, 36% of patients had lymphoma-associated hemophagocytic syndrome (LAHS), compared with 8% of the patients without BMI (8/103, P < 0.001).
  • The estimated 1-year overall survival (OS) rates of patients with LAHS in the BMI and non-BMI groups were 5 and 49%, respectively.
  • The increased levels of lactate dehydrogenase, fasting triglycerides and beta(2)-microglobulin between the BMI and non-BMI groups were not significantly different, but ferritin increased significantly and liver dysfunction-related diseases were seen more in the BMI group.
  • The estimated 2-year OS rate of the 67 patients with BMI, who did not lose to follow-up, was 22%, compared with 38% in the non-BMI group.
  • The median survival time of the 14 patients subjected to chemotherapy combined with L: -asparaginase was 365 days and that of the 7 patients undergoing hemopoietic stem cell transplantation (HSCT) was 575 days.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Lymphohistiocytosis, Hemophagocytic / drug therapy. Lymphohistiocytosis, Hemophagocytic / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Feb 1;99(3):815-21 [11806981.001]
  • [Cites] Haematologica. 1997 Mar-Apr;82(2):171-7 [9175321.001]
  • [Cites] Histol Histopathol. 2002 Apr;17 (2):539-54 [11962758.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Br J Haematol. 2004 Jan;124(1):4-14 [14675403.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):140-54 [15461619.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):151-9 [17387300.001]
  • [Cites] Eur J Cancer. 2002 Jan;38(1):75-81 [11750843.001]
  • [Cites] J Korean Med Sci. 2004 Apr;19(2):229-33 [15082896.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):342-9 [14716770.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Am J Clin Pathol. 1995 Jan;103(1):82-9 [7817951.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1278-82 [17475910.001]
  • [Cites] Br J Haematol. 1985 Oct;61(2):203-13 [4041367.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2000 Nov;21(11):577-9 [11225247.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):241-9 [12688340.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1601-8 [15378507.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Leuk Lymphoma. 2008 Jan;49(1):81-7 [18203016.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2007 Jul;28(7):454-7 [18072627.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):331-8 [2050367.001]
  • (PMID = 19728028.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7006-34-0 / Asparagine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


66. Tan BT, Seo K, Warnke RA, Arber DA: The frequency of immunoglobulin heavy chain gene and T-cell receptor gamma-chain gene rearrangements and Epstein-Barr virus in ALK+ and ALK- anaplastic large cell lymphoma and other peripheral T-cell lymphomas. J Mol Diagn; 2008 Nov;10(6):502-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The frequency of immunoglobulin heavy chain gene and T-cell receptor gamma-chain gene rearrangements and Epstein-Barr virus in ALK+ and ALK- anaplastic large cell lymphoma and other peripheral T-cell lymphomas.
  • We previously identified a relatively high frequency of B-cell proliferations along with simultaneous T-cell receptor gamma-chain gene (TRG) and immunoglobulin heavy chain gene (IGH) rearrangements in a series of angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified.
  • Here, we report on a series of 74 peripheral T-cell lymphoma (PTCL) cases composed entirely of specific PTCL subtypes, including 28 cases of ALK+ anaplastic large-cell lymphoma (ALCL), 35 cases of ALK- ALCL, and 11 cases that represent other specific PTCL subtypes.
  • We performed IGH and TRG gene rearrangement studies and in situ hybridization for Epstein-Barr virus (EBV) to determine the frequency of IGH clonality and to investigate the relationship between EBV, clonality, and associated B-cell proliferations.
  • Despite the detection of occasional IGH clones, there was no correlation between IGH clonality and EBV, and B-cell proliferations were not identified in any of the cases.
  • These findings suggest that other factors contribute to IGH clonality and demonstrate that, in the absence of an associated B-cell proliferation, IGH clonality occurs infrequently (8%) in specific PTCL subtypes.
  • [MeSH-major] Gene Rearrangement. Genes, T-Cell Receptor gamma. Herpesvirus 4, Human / immunology. Immunoglobulin Heavy Chains / genetics. Lymphoma, Large-Cell, Anaplastic / genetics. Lymphoma, T-Cell, Peripheral / genetics. Protein-Tyrosine Kinases / metabolism. Receptors, Antigen, T-Cell, gamma-delta / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2000 Aug;114(2):236-47 [10941339.001]
  • [Cites] Br J Haematol. 2007 Jul;138(1):31-43 [17555445.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2254-61 [10979974.001]
  • [Cites] Mol Pathol. 2000 Aug;53(4):194-200 [11040942.001]
  • [Cites] Mod Pathol. 2000 Dec;13(12):1269-79 [11144922.001]
  • [Cites] J Mol Diagn. 2000 May;2(2):92-6 [11272894.001]
  • [Cites] Diagn Mol Pathol. 2001 Jun;10(2):69-77 [11385314.001]
  • [Cites] J Mol Diagn. 2001 Nov;3(4):133-40 [11687596.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2315-23 [11895762.001]
  • [Cites] J Pathol. 2002 Oct;198(2):171-80 [12237876.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2134-41 [12357368.001]
  • [Cites] Am J Clin Pathol. 2002 Dec;118(6):848-54 [12472277.001]
  • [Cites] Lancet. 2003 Jan 18;361(9353):217-23 [12547545.001]
  • [Cites] J Mol Diagn. 2003 May;5(2):82-7 [12707372.001]
  • [Cites] Eur J Immunol. 2003 Jun;33(6):1593-602 [12778477.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):807-13 [12802918.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1834-44 [12970784.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3775-85 [12907442.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 1983 Jun;61(6):1138-45 [6404327.001]
  • [Cites] EMBO J. 1984 Jun;3(6):1209-19 [6086308.001]
  • [Cites] Blood. 1986 Jan;67(1):1-11 [3079640.001]
  • [Cites] Am J Clin Pathol. 1986 Apr;85(4):490-3 [2420169.001]
  • [Cites] Leukemia. 1987 Mar;1(3):235 [3669744.001]
  • [Cites] Clin Chim Acta. 1991 Apr;198(1-2):93-174 [1863986.001]
  • [Cites] J Clin Pathol. 1995 Nov;48(11):1045-50 [8543629.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]
  • [Cites] Leukemia. 1998 Jul;12(7):1081-8 [9665194.001]
  • [Cites] Leukemia. 1999 Feb;13(2):196-205 [10025893.001]
  • [Cites] Mol Diagn. 1999 Jun;4(2):119-33 [10462627.001]
  • [Cites] Mol Pathol. 1999 Apr;52(2):104-10 [10474690.001]
  • [Cites] J Mol Diagn. 2005 Oct;7(4):495-503 [16237219.001]
  • [Cites] Br J Dermatol. 2006 Jan;154(1):162-6 [16403112.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):466-75; quiz 527 [16931587.001]
  • [Cites] Leukemia. 2007 Feb;21(2):215-21 [17170730.001]
  • [Cites] Leukemia. 2007 Feb;21(2):207-14 [17170731.001]
  • [Cites] Diagn Mol Pathol. 2000 Sep;9(3):132-6 [10976719.001]
  • (PMID = 18832464.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell, gamma-delta; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC2570633
  •  go-up   go-down


67. Qubaja M, Audouin J, Moulin JC, Molina TJ, Le Tourneau A, Gaulard P, Straub P, Audhuy B, Diebold J: Nodal follicular helper T-cell lymphoma may present with different patterns. A case report. Hum Pathol; 2009 Feb;40(2):264-9
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal follicular helper T-cell lymphoma may present with different patterns. A case report.
  • We report the case of a 62-year-old patient presenting with 3 different patterns of follicular helper T-cell lymphoma.
  • The patient initially presented with angioimmunoblastic T-cell lymphoma.
  • A nodal relapse in the form of follicular T-cell lymphoma with a progressively transformed germinal center pattern occurred 8 years later.
  • Two years later, this was followed by another relapse presenting as a predominantly large-cell peripheral T-cell lymphoma, unspecified.
  • The immunophenotype showed a progressive increase in the proportion of cells expressing CD10, bcl-6, CXCL13, and programmed death-1 from the first to the last lymphoma.
  • [MeSH-major] Lymphoma, Follicular / pathology. Lymphoma, T-Cell / pathology. Neoplasms, Second Primary / pathology. T-Lymphocytes, Helper-Inducer / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760445.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


68. Mitarnun W, Suwiwat S, Pradutkanchana J: Epstein-Barr virus-associated extranodal non-Hodgkin's lymphoma of the sinonasal tract and nasopharynx in Thailand. Asian Pac J Cancer Prev; 2006 Jan-Mar;7(1):91-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated extranodal non-Hodgkin's lymphoma of the sinonasal tract and nasopharynx in Thailand.
  • Epstein-Barr virus (EBV) infection is highly associated with specific subtypes of malignant lymphoma.
  • In our previous report on nodal malignant lymphoma in Thailand, we found that 64% of classical Hodgkin's lymphoma (cHL), 51% of non-Hodgkin's lymphoma, T-cell (NHL-T), and 13% of non-Hodgkin's lymphoma, B-cell (NHL-B) were EBV-related.
  • In the present research, we conducted a retrospective study of primary extranodal non-Hodgkin's lymphoma of the sinonasal tract (e-NHL-ST) and primary extranodal non-Hodgkin's lymphoma of the nasopharynx (e-NHL-NP) in Southern Thailand, between 1997 and 2004.
  • EBV-encoded RNA (EBER) expression by in situ hybridization was performed in all cases and a T-cell receptor (TCR)-g gene rearrangement study was performed in NHL-T cases.
  • The percentages of e-NHL-ST and e-NHL-NP as compared to nodal malignant lymphoma were 3.7% and 6.8%, respectively.
  • Monoclonal bands of the TCR-gamma gene were detected in 71.4% of the extranodal NK/T-cell lymphomas, nasal type, patients; 50.0% of peripheral T-cell lymphoma, unspecified, patients; and one case of angioimmunoblastic T-cell lymphoma.
  • The study also indicates that most cases of extranodal NK/T-cell lymphoma, nasal type, are not the germline configuration of the TCR genes.
  • [MeSH-major] Herpesvirus 4, Human / isolation & purification. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology. Nasopharyngeal Neoplasms / virology. Paranasal Sinus Neoplasms / virology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Cohort Studies. DNA, Viral / analysis. Female. Humans. In Situ Hybridization. Incidence. Lymph Nodes / pathology. Lymphoma, T-Cell / epidemiology. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / virology. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Rate. Thailand / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16629523.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


69. Warnke RA, Jones D, Hsi ED: Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics. Am J Clin Pathol; 2007 Apr;127(4):511-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics.
  • Given their relative rarity, one of the primary diagnostic difficulties in nodal T-cell lymphomas is recognizing their range of histologic patterns.
  • This is complicated by the fact that most mature T-cell lymphomas retain some functional characteristics of nonneoplastic T cells, ie, the capacity to secrete cytokines and costimulate immune cell growth, and, thus, are associated with obscuring nonneoplastic immune cells.
  • Sessions 2 and 3 of the Society for Hematopathology/European Association for Haematopathology Workshop focused on these issues and conditions that may simulate T-cell lymphomas.
  • We summarize salient features of presented cases, including the varied patterns seen in angioimmunoblastic T-cell lymphoma (AITL) and other more poorly characterized morphologic and functional nodal T-cell lymphoma subsets.
  • Many cases illustrated the difficulties distinguishing AITL from peripheral T-cell lymphoma, unspecified, when the neoplasms manifest only some AITL features.
  • The usefulness of separately classifying T-cell lymphomas that demonstrate follicular, perifollicular, or T-zone patterns of infiltration; significance of immunophenotypically distinct subsets that express cytotoxic markers or have features of central memory T cells; diagnostic difficulties posed by B-cell proliferations that accompany T-cell lymphomas; and T-cell lymphoma mimics related to genetic disorders, immune dysregulation, and drug reactions are also discussed.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymph Nodes / pathology. Lymphoma, T-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17369127.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


70. Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, Bacci F, Falini B, Motta T, Paulli M, Artusi T, Piccioli M, Zinzani PL, Pileri SA: Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol; 2006 Jun 1;24(16):2472-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score.
  • PURPOSE: Although peripheral T-cell lymphoma, unspecified (PTCL/U), is the most common T-cell tumor in Western countries, no study to date has been based on the application of a wide panel of markers to a large series of patients and assessed the impact of phenotype on survival.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Ki-67 Antigen / analysis. Lymphoma, T-Cell, Peripheral / chemistry. Lymphoma, T-Cell, Peripheral / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636342.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD15; 0 / Antigens, CD2; 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Antigens, CD30; 0 / Antigens, CD4; 0 / Antigens, CD5; 0 / Antigens, CD7; 0 / Antigens, CD8; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


71. Wang XQ, Sino-US Leukemia Cooperative Group of Shanghai: [Cytogenetic study on 155 cases of non-Hodgkin' s lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2006 Oct;27(10):656-60
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytogenetic study on 155 cases of non-Hodgkin' s lymphoma].
  • OBJECTIVE: To investigate the relationship between histopathological subtype of non-Hodgkin' s lymphoma(NHL) and chromosomal abnormalities, and compare the difference of chromosomal abnormalities between China and the West.
  • RESULTS: Diffuse large B-cell lymphoma( DLBCL) constituted 38.1% of the cases followed by follicular lymphoma(FL) 17.4% , small lymphocytic lymphoma( SLL) 10.3% , peripheral T-cell lymphoma ( PTCL) ( unspecified) 8.4%, and angioimmunoblastic lymphoma 7.1%.
  • The incidence of chromosomal abnormalities among FL, SLL, DLBCL, anaplastic large cell lymphoma (ALCL) and precursor T-cell lymphoblastic lymphoma (TLBL) was 96.3% , 87.5% , 86.4%, 83.3% and 83.3%, respectively.
  • Normal karyotype was observed in 8/11 cases with angioimmunoblastic T-cell lymphoma patients.
  • The incidence of chromosomal abnormalities in angioimmunoblastic T-cell lymphoma was lower than that in the West.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Chromosome Structures. Cytogenetic Analysis. Female. Humans. In Situ Hybridization, Fluorescence. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343195.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


72. Dueck G, Chua N, Prasad A, Finch D, Stewart D, White D, van der Jagt R, Johnston J, Belch A, Reiman T: Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer; 2010 Oct 1;116(19):4541-8
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.
  • BACKGROUND: Novel therapies are needed to improve outcomes in T-cell lymphomas.
  • The authors report the interim results of a prospective multicenter trial evaluating lenalidomide in T-cell lymphomas.
  • METHODS: Patients with recurrent and refractory T-cell lymphomas other than mycosis fungoides and untreated patients ineligible for combination chemotherapy were prescribed oral lenalidomide (25 mg daily) on Days 1 to 21 of each 28-day cycle until disease progression, death, or unacceptable toxicity.
  • Responses were seen in anaplastic, angioimmunoblastic, and peripheral T-cell unspecified histologies.
  • CONCLUSIONS: In patients with recurrent and refractory T-cell lymphomas, oral lenalidomide monotherapy has clinical activity, and toxicity is consistent with the known safety profile of lenalidomide.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, T-Cell / drug therapy. Thalidomide / analogs & derivatives

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20572046.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  •  go-up   go-down


73. Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA: Expression of CD52 in peripheral T-cell lymphoma. Haematologica; 2007 Apr;92(4):566-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD52 in peripheral T-cell lymphoma.
  • Peripheral T-cell lymphoma unspecified (PTCL/U) is a rare tumor characterized by poor treatment response and a dismal prognosis.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, Neoplasm / biosynthesis. Glycoproteins / biosynthesis. Lymphoma, T-Cell, Peripheral / metabolism. T-Lymphocytes / metabolism

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488672.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 3A189DH42V / alemtuzumab
  •  go-up   go-down


74. Collins JA, Hernández AV, Hidalgo JA, Villena J, Sumire J, Delgado V, Salazar R, Almenara Hospital AIDS Working Group: High proportion of T-cell systemic non-Hodgkin lymphoma in HIV-infected patients in Lima, Peru. J Acquir Immune Defic Syndr; 2005 Dec 15;40(5):558-64
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High proportion of T-cell systemic non-Hodgkin lymphoma in HIV-infected patients in Lima, Peru.
  • OBJECTIVE: Few reports have described the clinical and pathologic characteristics of HIV-related systemic non-Hodgkin lymphoma (sNHL) in developing countries.
  • Clinical characteristics at diagnosis included age, gender, risk behavior, previous AIDS diagnosis, opportunistic diseases, previous highly active antiretroviral therapy, Karnofsky score, origin, clinical stage and B-cell symptoms of sNHL, and CD4 cell count.
  • The CD4 cell count median value was 111 cells/microL (n = 25).
  • Twenty-four cases (73%) were B-cell sNHL, and 9 cases (27%) were T-cell sNHL, both from peripheral cells.
  • Nineteen cases of sNHL were extranodal: 15 of B-cell origin and 4 of T-cell origin.
  • Eighteen cases of B-cell sNHL had diffuse large cell histologic findings, and all cases of T-cell sNHL were unspecified.
  • Although there were no significant differences in clinical characteristics between phenotypes, patients with T-cell sNHL had less aggressive disease and a better survival rate.
  • CONCLUSIONS: A high proportion of T-cell sNHL cases was found at an HIV reference center in Peru.
  • Clinical characteristics were similar between B-cell and T-cell lymphoma patients.
  • T-cell lymphoma was less aggressive, and patients with T-cell lymphoma had a better survival rate than those with B-cell lymphoma.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology. Lymphoma, T-Cell / epidemiology


75. Reichard KK, Schwartz EJ, Higgins JP, Narasimhan B, Warnke RA, Natkunam Y: CD10 expression in peripheral T-cell lymphomas complicated by a proliferation of large B-cells. Mod Pathol; 2006 Mar;19(3):337-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 expression in peripheral T-cell lymphomas complicated by a proliferation of large B-cells.
  • CD10 expression by the neoplastic T cells in angioimmunoblastic T-cell lymphoma was recently described.
  • As cases of peripheral T-cell lymphoma, unspecified, fail to show similar CD10 expression, this feature helps discriminate between these two entities, particularly in cases exhibiting morphologic overlap.
  • Given these findings, we studied CD10 expression in a subtype of peripheral T-cell lymphoma known as peripheral T-cell lymphoma complicated by a proliferation of large B cells and compared it with angioimmunoblastic T-cell lymphoma and angioimmunoblastic T-cell lymphoma with a large B-cell proliferation.
  • A total of 33 cases were identified including peripheral T-cell lymphoma complicated by a proliferation of large B cells (10), angioimmunoblastic T-cell lymphoma (10) and angioimmunoblastic T-cell lymphoma with a large B-cell proliferation (13).
  • Diagnoses were established by hematoxylin and eosin (H&E) stain, immunohistochemistry and/or molecular findings (polymerase chain reaction for T-cell receptor-gamma gene rearrangement).
  • Two of 10 cases of peripheral T-cell lymphoma complicated by a proliferation of large B cells showed aberrant CD10 expression (20%) compared to 9/10 cases of angioimmunoblastic T-cell lymphoma (90%) and 8/13 of angioimmunoblastic T-cell lymphoma with a large B-cell proliferation (62%).
  • One case each of angioimmunoblastic T-cell lymphoma and angioimmunoblastic T-cell lymphoma with a large B-cell proliferation showed a rare, but not unequivocal, CD10+ atypical cell.
  • Four cases of angioimmunoblastic T-cell lymphoma with a large B-cell proliferation were CD10 negative.
  • Of the 2 CD10+ peripheral T-cell lymphoma complicated by a proliferation of large B cells, one had no H&E or IHC features of angioimmunoblastic T-cell lymphoma and showed only a rare positive cell.
  • The second case, a lung biopsy, exhibited diffuse CD10 tumor cell positivity.
  • Our data indicate that only 20% of cases of peripheral T-cell lymphoma complicated by a proliferation of large B cells show CD10 expression by the neoplastic T cells in contrast to angioimmunoblastic T-cell lymphoma and angioimmunoblastic T-cell lymphoma with a large B-cell proliferation which exhibit CD10 staining in 90 and 62% of cases, respectively.
  • [MeSH-major] B-Lymphocytes / pathology. Cell Proliferation. Lymphoma, T-Cell, Peripheral / pathology. Neprilysin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD20 / analysis. Antigens, CD3 / analysis. Diagnosis, Differential. Female. Herpesvirus 4, Human / genetics. Humans. Immunohistochemistry. In Situ Hybridization. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. RNA, Viral / genetics. RNA, Viral / metabolism. Receptors, Complement 3d / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400325.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 34233
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / RNA, Viral; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


76. Li T, Zhang B, Ye Y, Yin H: Immunohistochemical and genetic analysis of Chinese nasal natural killer/T-cell lymphomas. Hum Pathol; 2006 Jan;37(1):54-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and genetic analysis of Chinese nasal natural killer/T-cell lymphomas.
  • Nasal natural killer/T-cell lymphoma (N-NK/T-L) is prevalent in China.
  • To further characterize this neoplasm, 36 cases of N-NK/T-L from 304 cases of malignant lymphomas in the north China area were investigated by histopathology, immunophenotyping, and genomic analysis of c-kit, in comparison with 11 cases of B-cell lymphoma (BCL) at the same region and 5 cases of nodal peripheral T-cell lymphoma (PTCL) (unspecified).
  • Thirty cases (83.3%) were positive for T-cell intracellular antigen-1, 22 (61.1%) for granzyme B, 18 (50.0%) for CD56, and 11 (30.6%) for CD30, whereas none was positive for CD117.
  • All 5 cases of PTCL displayed positive staining for CD45RO and T-cell intracellular antigen-1, 3 cases for CD3epsilon, but only 1 case for granzyme B.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell, Peripheral / pathology. Mutation. Nose Neoplasms / pathology. Proto-Oncogene Proteins c-kit / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. China. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Humans. Immunohistochemistry. Immunophenotyping. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360416.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


77. Ballester B, Ramuz O, Gisselbrecht C, Doucet G, Loï L, Loriod B, Bertucci F, Bouabdallah R, Devilard E, Carbuccia N, Mozziconacci MJ, Birnbaum D, Brousset P, Berger F, Salles G, Briére J, Houlgatte R, Gaulard P, Xerri L: Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene; 2006 Mar 9;25(10):1560-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas.
  • The classification of peripheral T-cell lymphomas (PTCL) is still a matter of debate.
  • To establish a molecular classification of PTCL, we analysed 59 primary nodal T-cell lymphomas using cDNA microarrays, including 56 PTCL and three T-lymphoblastic lymphoma (T-LBL).
  • The expression profiles could discriminate angioimmunoblastic lymphoma, anaplastic large-cell lymphoma and T-LBL.
  • In contrast, cases belonging to the broad category of 'PTCL, unspecified' (PTCL-U) did not share a single molecular profile.
  • The U2 subgroup was associated with overexpression of genes involved in T-cell activation and apoptosis, including NFKB1 and BCL-2.
  • [MeSH-major] Gene Expression Profiling. Lymph Nodes / pathology. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288225.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


78. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M: Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood; 2010 Nov 4;116(18):3418-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
  • To evaluate outcome and prognosis of patients with T-cell lymphoma we analyzed 343 patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
  • Two hundred eighty-nine patients belonged to 1 of the 4 major T-cell lymphoma subtypes: anaplastic large cell lymphoma (ALCL), anaplastic large cell lymphoma kinase (ALK)-positive (n = 78); ALCL, ALK-negative (n = 113); peripheral T-cell lymphoma, unspecified (PTCLU; n = 70); and angioimmunoblastic T-cell lymphoma (AITL; n = 28).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Humans. Killer Cells, Natural / pathology. Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / drug therapy. Lymphoma, Extranodal NK-T-Cell / pathology. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Prognosis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use. Young Adult


79. Lee MY, Tsou MH, Tan TD, Lu MC: Clinicopathological analysis of T-cell lymphoma in Taiwan according to WHO classification: high incidence of enteropathy-type intestinal T-cell lymphoma. Eur J Haematol; 2005 Sep;75(3):221-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological analysis of T-cell lymphoma in Taiwan according to WHO classification: high incidence of enteropathy-type intestinal T-cell lymphoma.
  • OBJECTIVES: The clinicopathological characteristics of malignant lymphomas vary according to geography, especially for the T-cell lymphoma (TCL).
  • The incidence of TCL in malignant lymphoma was 12.3%.
  • The most prevalent histologic subtype was peripheral T-cell lymphoma (PTCL), followed by nasal T-cell/Natural killer- (T-/NK-) cell lymphoma, T-lymphoblastic lymphoma (LBL), anaplastic large cell lymphoma, and enteropathy-type intestinal lymphoma (ETCL).
  • The most common histological subtypes are PTCL, unspecified and T-/NK-cell lymphoma.
  • [MeSH-major] Intestinal Neoplasms / pathology. Lymphoma, T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2005.
  • (PMID = 16104878.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


80. Liao JB, Chuang SS, Chen HC, Tseng HH, Wang JS, Hsieh PP: Clinicopathologic analysis of cutaneous lymphoma in taiwan: a high frequency of extranodal natural killer/t-cell lymphoma, nasal type, with an extremely poor prognosis. Arch Pathol Lab Med; 2010 Jul;134(7):996-1002
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of cutaneous lymphoma in taiwan: a high frequency of extranodal natural killer/t-cell lymphoma, nasal type, with an extremely poor prognosis.
  • CONTEXT: Primary cutaneous lymphoma is an uncommon, extranodal lymphoma, and it is usually more indolent with a better prognosis than its histologically similar systemic counterpart is.
  • OBJECTIVES: To illustrate the clinicopathologic features of cutaneous lymphomas in Taiwan and to compare the relative frequencies of subtypes of cutaneous lymphoma among different geographic areas.
  • Among primary cutaneous lymphomas, 23 cases (74%) were T-cell or natural killer-cell lymphomas, and 8 cases (26%) were B-cell lymphomas.
  • The most common types were extranodal natural killer/T-cell lymphoma, nasal type, and primary cutaneous peripheral T-cell lymphoma, unspecified (5 cases each; 16%).
  • In contrast with other primary cutaneous B-cell and T-cell lymphomas, either primary or secondary extranodal cutaneous natural killer/T-cell lymphomas, nasal type, had extremely poor prognoses (1-year overall survival, 0%).
  • CONCLUSIONS: This study showed that the frequency of subtypes of primary cutaneous lymphoma varied in different geographic areas.
  • Compared with the Western countries, there was a higher frequency of extranodal natural killer/T-cell lymphoma, nasal type, and a lower frequency of mycosis fungoides in Taiwan.
  • Extranodal natural killer/T-cell lymphoma, nasal type, also had an extremely poor prognosis compared with other lymphomas.
  • [MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology. Lymphoma / physiopathology. Lymphoma, T-Cell, Cutaneous / epidemiology. Nose Neoplasms / epidemiology. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20586627.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


81. Medina-Franco H, Germes SS, Maldonado CL: Prognostic factors in primary gastric lymphoma. Ann Surg Oncol; 2007 Aug;14(8):2239-45
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in primary gastric lymphoma.
  • BACKGROUND: There is not a gold standard in the treatment of primary gastric lymphoma (PGL).
  • RESULTS: We identified 41 patients of which 19 (46.3%) were classified as large-cell lymphoma, 16 (39.0%) as low-grade MALT, and 6 (14.6%) patients as lymphoma unspecified.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17546474.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


82. Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, Yamazaki E, Sakai R, Tamaru J, Kishi K, Kanamori H, Higashihara M, Hotta T, Ishigatsubo Y: Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol; 2007 Dec;82(12):1106-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection.
  • Rheumatoid arthritis (RA) is associated with an increased risk of developing lymphoma.
  • We investigated the relationship between EBV latent infection and methotrexate (MTX)-associated lymphoma in RA patients.
  • Nine patients were diagnosed with non-Hodgkin's lymphoma (NHL) during MTX treatment for RA in a multicenter study.
  • The pathologic findings were consistent with diffuse large B-cell lymphoma in 8 patients and peripheral T-cell lymphoma, unspecified in 1.
  • [MeSH-major] Arthritis, Rheumatoid / complications. Arthritis, Rheumatoid / drug therapy. Epstein-Barr Virus Infections / complications. Lymphoma, Non-Hodgkin / chemically induced. Methotrexate / therapeutic use


83. Krivolapov IuA: [Histological and immunophenotypical characteristics of peripheral T-cell lymphomas]. Arkh Patol; 2005 Mar-Apr;67(2):17-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histological and immunophenotypical characteristics of peripheral T-cell lymphomas].
  • Histopathologic features of immunohistochemically confirmed 37 nodal peripheral T-cell lymphomas are described.
  • Unspecified and 10 angioimmunoblastic T-cell lymphomas were analyzed.
  • Delineation between peripheral T-cell lymphoma, unspecified and angioimmunoblastic T-cell lymphoma needs evaluation of follicular dendritic cell pattern.
  • The results suggest that detection of histopathologic features typical for peripheral T-cell lymphomas gives an opportunity to compose optimal panel for immunotyping which is absolutely necessary.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / immunology. Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938113.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


84. Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, Yamaguchi M, Kurosawa M, Tsukasaki K, Kasai M, Tobinai K, Kaba H, Mukai K, Nakamura S, Ohshima K, Hotta T, Shimoyama M: Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma; 2010 May;51(5):813-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas.
  • Peripheral T- and NK-cell lymphomas (PT/NKCLs) are relatively rare, and few studies have validated the International Prognostic Index (IPI) for PT/NKCLs in prospective clinical trials.
  • In a univariate analysis, low total serum protein (TP) and albumin levels, gastrointestinal tract involvement, and histologic subtype (extranodal NK/T-cell lymphoma, nasal type, and peripheral T-cell lymphoma, unspecified) were significantly associated with reduced survival.
  • [MeSH-major] Biomarkers, Tumor / blood. Blood Proteins / metabolism. Lymphoma, Extranodal NK-T-Cell / blood. Lymphoma, Large B-Cell, Diffuse / blood. Lymphoma, T-Cell, Peripheral / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367565.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins
  •  go-up   go-down


85. Uemura Y, Imai T, Nakajim T, Urata T, Doi H: [A case of refractory pulmonary peripheral T cell lymphoma successfully treated with Cisplatin Plus Gemcitabine Plus Solumedrol]. Nihon Kokyuki Gakkai Zasshi; 2010 Jan;48(1):28-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of refractory pulmonary peripheral T cell lymphoma successfully treated with Cisplatin Plus Gemcitabine Plus Solumedrol].
  • Pathological examination of the esophagus biopsy specimens showed an unspecified peripheral T cell lymphoma.
  • After an autologous peripheral blood stem cell transplantation, a complete response was observed in the patient.
  • However, a lymphoma relapse was diagnosed in the lung in September 2008.
  • The relapsed lung lymphoma was tolerant to EPOCH therapy.
  • The refractory pulmonary peripheral T cell lymphoma was remarkably reduced by PEGS therapy.
  • PEGS therapy is useful for relapsed peripheral T cell lymphoma cases that tolerated standard chemotherapy.
  • An allogenic hematopoietic stem cell transplantation or new molecular target therapy might be finally selected for refractory peripheral T cell lymphoma.
  • We think that PEGS therapy is a useful treatment for refractory peripheral T cell lymphoma before allogenic transplantation or new molecular target drug treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lymphoma, T-Cell, Peripheral / drug therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163018.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0W860991D6 / Deoxycytidine; 5GMR90S4KN / Methylprednisolone Hemisuccinate; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


86. Nelson M, Horsman DE, Weisenburger DD, Gascoyne RD, Dave BJ, Loberiza FR, Ludkovski O, Savage KJ, Armitage JO, Sanger WG: Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br J Haematol; 2008 May;141(4):461-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma.
  • Cytogenetic correlations among most types of peripheral T-cell lymphoma (PTCL) have not been very informative to date.
  • This study aimed to identify recurrent chromosomal abnormalities in angioimmunoblastic T-cell lymphoma (AITL), ALK-negative anaplastic large cell lymphoma (ALK-ALCL) and peripheral T-cell lymphoma, unspecified (PTCL-US), and to evaluate their prognostic value.
  • [MeSH-major] Chromosome Aberrations. Lymphoma, T-Cell, Peripheral / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Humans. Immunoblastic Lymphadenopathy / genetics. Karyotyping. Lymphoma, Large-Cell, Anaplastic / genetics. Male. Middle Aged. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341637.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


87. Feng YF, Wu QL, Zong YS: Correlation of immunophenotype of sinonasal non-Hodgkin's lymphoma to Epstein-Barr virus infection. Ai Zheng; 2007 Nov;26(11):1170-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of immunophenotype of sinonasal non-Hodgkin's lymphoma to Epstein-Barr virus infection.
  • BACKGROUND & OBJECTIVE: There are differences in the prevalence rate and composition of immunophenotypes of sinonasal non-Hodgkin's lymphoma (NHL) depending on the geography.
  • Forty-four sinonasal NHLs (44/57, 77.19%) were NK/T-cell lymphoma, nasal type, all of which were infected with EBV.
  • Among them, 37 patients (84.09%) appeared to be NK-cell neoplasm (EBV+/CD56+), and 7 cases (15.91%) showed an EBV+/CD56-cytotoxic T-cell phenotype.
  • Eleven cases (11/57, 19.30%) were B-cell lymphoma.
  • There were 6 cases of diffuse large B-cell immunophenotype, 2 cases of Burkitt (Burkitt-like) lymphoma (EBV+), 1 case of extramedullary plasmacytoma (EBV+), 1 case of MALT-lymphoma (EBV-), and 1 case of small lymphocytic lymphoma (EBV-).
  • Only 2 cases (2/57, 3.51%; EBV-) were peripheral T-cell lymphoma, unspecified.
  • The del-LMP1 EBV strain harbored in 25 out of 37 available DNA samples of NK/T-cell lymphoma (25/37, 67.57%); and the wt-LMP1 EBV strain was found in 12 samples (12/37, 32.43%).
  • CONCLUSION: The most common sinonasal NHL is the NK/T-cell lymphoma, nasal type, which can be further subclassified into NK-cell neoplasm (EBV+/CD56+) and EBV+/CD56-cytotoxic T-cell phenotype.
  • The major EBV strain in NK/T-cell lymphomas is del-LMP1 strain.
  • [MeSH-major] Epstein-Barr Virus Infections. Immunophenotyping. Lymphoma, Non-Hodgkin / virology. Nasopharyngeal Neoplasms / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD56 / analysis. Child. Child, Preschool. China. Female. Humans. Lymphoma, Extranodal NK-T-Cell / immunology. Lymphoma, Extranodal NK-T-Cell / virology. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / virology. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / virology. Male. Middle Aged. Viral Matrix Proteins / analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991313.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


88. Li Z, Liu WP, Tang Y, Jiang LL, Zhang WY, Bi CF, Li GD: [Splenic T-cell and NK-cell lymphomas: a clinicopathologic and immunophenotypic analysis of 9 cases]. Zhonghua Xue Ye Xue Za Zhi; 2007 Apr;28(4):217-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Splenic T-cell and NK-cell lymphomas: a clinicopathologic and immunophenotypic analysis of 9 cases].
  • OBJECTIVE: To explore the clinicopathologic features and diagnosis of splenic T-cell and NK-cell neoplasms.
  • METHODS: Nine cases of splenic T-cell and NK-cell neoplasms were collected and studied by morphology, immunophenotyping, EBER in situ hybridization and TCR-gamma gene rearrangement.
  • RESULTS: Among the 9 cases, hepatosplenic T-cell lymphoma (HSTCL) and extranodal nasal type NK/T-cell lymphoma (NK/TCL) were both of 4 cases, and the remaining one was peripheral T-cell lymphoma, unspecified (PTL, unspecified).
  • Five patients including 2 with HSTCL, 2 with extranodal nasal type NK/TCL and one with PTL, unspecified died, with survival times ranged from 1 to 10 months.
  • CONCLUSION: Splenic T-cell and NK-cell neoplasms are a group of uncommon lymphomas with heterogeneous clinicopathologic features and poor prognosis.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / pathology. Lymphoma, T-Cell, Peripheral / pathology. Splenic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17877195.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


89. Murakami YI, Yatabe Y, Sakaguchi T, Sasaki E, Yamashita Y, Morito N, Yoh K, Fujioka Y, Matsuno F, Hata H, Mitsuya H, Imagawa S, Suzuki A, Esumi H, Sakai M, Takahashi S, Mori N: c-Maf expression in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol; 2007 Nov;31(11):1695-702
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-Maf expression in angioimmunoblastic T-cell lymphoma.
  • We previously examined c-Maf expression in various T-cell lymphomas by reverse-transcription polymerase chain reaction and found extremely elevated c-Maf levels in angioimmunoblastic T-cell lymphoma (AILT).
  • In this study, we examined T-cell lymphomas for c-Maf and cyclin expression immunohistochemically.
  • Of 93 cases of T-cell lymphomas we investigated in the current study, c-Maf expression was seen in 23 out of 31 cases of AILT, 3 out of 11 of adult T-cell leukemia/lymphoma, 4 out of 19 of peripheral T-cell lymphoma, unspecified [PTCL(U)], and 0 out of 11 cases of mycosis fungoides, 0 out of 11 of anaplastic large cell lymphoma, and 1 out of 10 of extranodal NK/T-cell lymphoma, nasal type.
  • Additionally, cyclins D1 and D2, which stimulate cell cycle progression, were overexpressed in a large number of the c-Maf-positive AILT samples.
  • Quantitative reverse-transcription polymerase chain reaction analysis also showed that c-Maf was overexpressed in 8/31 cases of AILT, 0/19 cases of PTCL(U), 0/11 cases of anaplastic large cell lymphoma, 0/10 cases of extranodal NK/T-cell lymphoma, nasal type, and 2/8 cases of multiple myeloma, presenting significant difference between AILT and PTCL(U) (P=0.016, chi test).
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunoblastic Lymphadenopathy / metabolism. Lymphoma, T-Cell / chemistry. Proto-Oncogene Proteins c-maf / analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059226.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD4; 0 / Antigens, CD43; 0 / Biomarkers, Tumor; 0 / CCND2 protein, human; 0 / Cyclin D; 0 / Cyclin D2; 0 / Cyclins; 0 / MAF protein, human; 0 / Proto-Oncogene Proteins c-maf; 0 / RNA, Messenger; 0 / UN1 sialoglycoprotein, human; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


90. Grau S, Schueller U, Weiss C, Tonn JC: Primary meningeal T-cell lymphoma at the clivus mimicking a meningioma. World Neurosurg; 2010 Oct-Nov;74(4-5):513-6
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary meningeal T-cell lymphoma at the clivus mimicking a meningioma.
  • BACKGROUND: Most primary lymphomas of the central nervous system (CNS) are of B-cell origin and are found intra-axially, with a few reported cases of skull base tumors involving the upper clivus or sellar region or both.
  • In this case, a tumor resembling a clivus meningioma without osseous involvement was surgically removed and turned out to be a primary T-cell lymphoma.
  • The final diagnosis was peripheral T-cell lymphoma, not otherwise unspecified.
  • CONCLUSIONS: Although a very rare entity among primary T-cell lymphomas of the CNS, these tumors also can occur as skull base lesions without involvement of the bone.
  • [MeSH-major] Cranial Fossa, Posterior / surgery. Infratentorial Neoplasms / diagnosis. Lymphoma, T-Cell / diagnosis. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Skull Base Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21492604.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Kim MK, Kim S, Lee SS, Sym SJ, Lee DH, Jang S, Park CJ, Chi HS, Huh J, Suh C: High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol; 2007 Jun;86(6):435-42
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
  • Although the role of high dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) in the treatment of aggressive lymphoma has been established in several large prospective studies, its effectiveness in patients with peripheral T cell lymphoma (PTCL) has not been defined.
  • Twenty patients had PTCL-U (peripheral T cell lymphoma, unspecified), 10 had extranodal natural killer/T cell lymphoma, 5 had anaplastic large cell lymphoma, 3 had angioimmunoblastic T cell lymphoma, 1 had hepatosplenic gammasigma T cell lymphoma, and 1 had disseminated mycosis fungoides.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Graft Survival. Hematopoietic Stem Cell Mobilization / methods. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Salvage Therapy. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17256144.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM: BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol; 2005 Oct;36(10):1113-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders.
  • B cell-activating factor receptor (BAFF-R) is one of three known receptors for BAFF, a critical regulator of B- and T-cell function.
  • In mice, BAFF-R is required for B-cell maturation and survival, and in mice and humans, the overproduction of BAFF is associated with autoimmune disease.
  • We sought to determine the normal pattern of BAFF-R expression at specific stages of B- and T-cell development and whether this pattern of expression corresponds with related B- and T-cell neoplasms.
  • In reactive lymphoid tissues, BAFF-R is expressed by B cells colonizing the mantle zones, by a subset of cells within germinal centers, and rare cells in the interfollicular T-cell zone.
  • Seventy-seven (78%) of 116 cases of B-cell lymphoproliferative disorders were BAFF-R-positive by immunohistochemical and/or flow cytometric immunophenotypic analysis, including most cases of mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, and diffuse large B-cell lymphoma.
  • In contrast, cases of precursor B lymphoblastic lymphoma, Burkitt lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma exhibit weak to negative staining for BAFF-R.
  • All cases of classical Hodgkin lymphoma and T-cell lymphomas were BAFF-R-negative, including all cases of anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, angioimmunoblastic T-cell lymphoma, and peripheral T-cell lymphoma, unspecified.
  • These findings highlight BAFF-R as a marker of both normal and neoplastic B cells and raise the possibility that BAFF-R expression is necessary for the survival of a subset of neoplastic B lymphocytes analogous to its known role in promoting normal B-cell maturation and survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226112.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Interleukin-4
  •  go-up   go-down


93. Hughes M, Morrison A, Jackson R: Primary bladder lymphoma: management and outcome of 12 patients with a review of the literature. Leuk Lymphoma; 2005 Jun;46(6):873-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bladder lymphoma: management and outcome of 12 patients with a review of the literature.
  • Primary bladder non-Hodgkin's lymphoma (NHL) is rare.
  • Using the Scotland and Newcastle lymphoma group database, 12 patients with primary bladder lymphoma were identified between 1980 and 2001, the largest single group of patients available to date.
  • Six cases were low-grade extranodal marginal zone lymphoma, 4 diffuse large B-cell lymphoma, one an ALK 1 positive anaplastic large cell lymphoma (ALKoma) and one a low-grade lymphoma unspecified.
  • A review of 88 additional cases in the literature support the findings that primary bladder lymphoma is associated with a good prognosis.
  • Patients with low-grade extranodal marginal zone lymphoma may respond well to simple therapies.
  • Patients with diffuse large B-cell lymphoma respond well to first-line chemotherapy regimens.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019532.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


94. Kikukawa M, Umahara T, Kikawada M, Kanaya K, Sakurai H, Shin K, Mori M, Iwamoto T: Peripheral T-cell lymphoma presenting as myelofibrosis with the expression of basic fibroblast growth factor. Geriatr Gerontol Int; 2009 Dec;9(4):395-8
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma presenting as myelofibrosis with the expression of basic fibroblast growth factor.
  • Myelofibrosis is often observed in chronic myeloproliferative disorders (CMPD), but non-Hodgkin's lymphoma with diffuse myelofibrosis is rare.
  • We describe an elderly case with peripheral T-cell lymphoma-unspecified (PTCL) presenting as diffuse myelofibrosis.
  • In addition, in situ hybridization revealed that infiltrating lymphoma cells expressed bFGF mRNA.
  • [MeSH-major] Fibroblast Growth Factor 2 / metabolism. Lymphoma, T-Cell, Peripheral / complications. Lymphoma, T-Cell, Peripheral / metabolism. Primary Myelofibrosis / complications. Primary Myelofibrosis / metabolism

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20002760.001).
  • [ISSN] 1447-0594
  • [Journal-full-title] Geriatrics & gerontology international
  • [ISO-abbreviation] Geriatr Gerontol Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


95. Go JH: Altered expression of Smad proteins in T or NK-cell lymphomas. Cancer Res Treat; 2008 Dec;40(4):197-201
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of Smad proteins in T or NK-cell lymphomas.
  • MATERIALS AND METHODS: Immunohistochemistry for Smad3 and Smad4 was performed on paraffin-embedded tissue sections collected from 26 T- or NK-cell lymphomas.
  • All lymphoblastic lymphomas showed strong positivity in most of tumor cells, but one unspecified peripheral lymphoma, two nasal NK/T cell lymphomas, and one anaplastic large cell lymphoma were negative for Smad4.
  • CONCLUSIONS: These results suggest that TGF-beta-specific Smads may be actively involved in signal transduction in lymphoid organs and that Smad-mediated TGF-beta signaling pathways are operative in malignant lymphoma.
  • In addition, loss of Smad4 expression might be associated with development of some T-cell lymphomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1998 Mar 6;92(5):645-56 [9506519.001]
  • [Cites] Int J Hematol. 1997 Feb;65(2):97-104 [9071813.001]
  • [Cites] Mol Cell Biol. 1996 Jul;16(7):3480-9 [8668164.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6002-6 [8016105.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):249-55 [7681031.001]
  • [Cites] Am J Pathol. 1990 Jun;136(6):1209-14 [2356855.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):552-9 [15295048.001]
  • [Cites] Int Immunol. 2003 Dec;15(12):1401-14 [14645149.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1731-7 [12970772.001]
  • [Cites] Pathol Res Pract. 2002;198(5):333-7 [12092769.001]
  • [Cites] Nat Rev Immunol. 2002 Jan;2(1):46-53 [11905837.001]
  • [Cites] J Hematother Stem Cell Res. 2001 Feb;10(1):67-74 [11276360.001]
  • [Cites] Dev Dyn. 2001 Feb;220(2):141-54 [11169847.001]
  • [Cites] Exp Cell Res. 2000 Nov 25;261(1):250-9 [11082295.001]
  • [Cites] J Biol Chem. 2000 Dec 8;275(49):38363-70 [10995749.001]
  • [Cites] Cell Growth Differ. 2000 Jan;11(1):1-10 [10672898.001]
  • [Cites] J Biol Chem. 2000 Jan 21;275(3):2115-22 [10636916.001]
  • [Cites] Nat Rev Immunol. 2007 Jun;7(6):443-53 [17525753.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2854-61 [10515889.001]
  • [Cites] EMBO J. 1999 Mar 1;18(5):1280-91 [10064594.001]
  • [Cites] Cell. 1998 Sep 18;94(6):703-14 [9753318.001]
  • (PMID = 19688130.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2697478
  • [Keywords] NOTNLM ; Etiology / Lymphoma / Smad proteins / T lymphocytes
  •  go-up   go-down


96. Okamoto A, Namura K, Uchiyama H, Kajita Y, Inaba T, Nakamura S, Shimazaki C: Cytotoxic T-cell non-Hodgkin's lymphoma of the thyroid gland. Am J Hematol; 2005 Sep;80(1):77-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic T-cell non-Hodgkin's lymphoma of the thyroid gland.
  • An 86-year-old female was diagnosed with peripheral T-cell lymphoma, unspecified, which affected only her thyroid gland.
  • Lymphoma cells were TIA-1(+), suggesting cytotoxic T-cell origin.
  • This is the first case of primary thyroid lymphoma of cytotoxic T-cell origin that showed spontaneous regression.
  • [MeSH-major] Lymphoma, Non-Hodgkin / surgery. Lymphoma, T-Cell / surgery. Thyroid Neoplasms / surgery

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16138337.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA-Binding Proteins; 148592-68-1 / TIAL1 protein, human
  •  go-up   go-down


97. Katayama Y, Okamura A, Nishikawa S, Hato A, Shimoyama M, Yamamoto K, Hayashi Y, Matsui T: [Bone marrow-restricted involvement of T-cell granular lymphocyte leukemia]. Rinsho Ketsueki; 2007 Jul;48(7):576-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bone marrow-restricted involvement of T-cell granular lymphocyte leukemia].
  • Flow cytometric and histological analyses revealed that these cells were positive for CD3, TCRalphabeta, granzyme B, and the diagnosis of T-cell granular lymphocyte leukemia (T-GLL) with myelofibrosis was made.
  • This is an overlap case of T-GLL and peripheral T-cell lymphoma, unspecified (PTCLu).
  • [MeSH-major] Bone Marrow / pathology. Leukemia, T-Cell / pathology. Leukemic Infiltration. T-Lymphocytes / pathology
  • [MeSH-minor] Aged. Antigens, CD20 / analysis. Cell Proliferation. Diagnosis, Differential. Female. Humans. Lymphoma, T-Cell / pathology. Primary Myelofibrosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695308.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD20
  •  go-up   go-down


98. Stacchini A, Demurtas A, Aliberti S, Francia di Celle P, Godio L, Palestro G, Novero D: The usefulness of flow cytometric CD10 detection in the differential diagnosis of peripheral T-cell lymphomas. Am J Clin Pathol; 2007 Nov;128(5):854-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of flow cytometric CD10 detection in the differential diagnosis of peripheral T-cell lymphomas.
  • We studied the histologic and multiparameter flow cytometry (MFC) features of 12 cases of angioimmunoblastic T-cell lymphoma (AITL), 13 of mature T-cell lymphoma, and 25 control cases of reactive lymphoid hyperplasia to evaluate the role of CD10 in the differential diagnosis of peripheral T-cell lymphomas (PTCLs).
  • Mature T-cell lymphoma showed a more heterogeneous altered immunophenotypic pattern, and 2 cases of PTCL, unspecified, had clear evidence of aberrant CD10 expression on T cells.
  • A small physiologic CD3+/CD4+/CD10+ T-cell population was detected by MFC in all control cases tested (range, 0.28%-4.71%), suggesting that a normal subset of peripheral CD10+ T cells exists.
  • CD10 was a highly sensitive but incompletely specific phenotypic marker for diagnosing AITL; the differential diagnosis of PTCL, unspecified, must be related with traditional histologic features.
  • [MeSH-major] Flow Cytometry / methods. Lymphoma, T-Cell, Peripheral / chemistry. Lymphoma, T-Cell, Peripheral / diagnosis. Neprilysin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951210.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


99. Tong H, Ren Y, Liu H, Xiao F, Mai W, Meng H, Qian W, Huang J, Mao L, Tong Y, Wang L, Qian J, Jin J: Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. Leuk Lymphoma; 2008 Jan;49(1):81-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome.
  • T-cell lymphoma-associated hemophagocytic syndrome (T-LAHS) has been frequently reported in Asian countries and is considered with extremely poor prognosis.
  • To summarize its clinical characteristics and explore its early diagnosis and treatment, we retrospectively analyzed the records of 113 patients with aggressive T cell lymphoma, of which 28 were associated with LAHS.
  • According to WHO classification (2001), 22 cases were classified into peripheral T-cell lymphoma (unspecified), 2 into extranodal NK/T-cell lymphoma, and 4 into systemic anaplastic large cell lymphoma.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / pathology. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18203016.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


100. Pongpruttipan T, Sitthinamsuwan P, Rungkaew P, Ruangchira-urai R, Vongjirad A, Sukpanichnant S: Pitfalls in classifying lymphomas. J Med Assoc Thai; 2007 Jun;90(6):1129-36
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHOD: Newly diagnosed lymphoma cases from 1 July 2002 to 30 June 2003 at Siriraj Hospital were included for two rounds of individually blinded review by a hematopathologist, two general pathologists, and three pathology residents.
  • RESULTS: One hundred and four lymphoma cases included 61 diffuse large B-cell lymphoma (DLBCL, 58.6%), 12 MALT lymphoma (11.5%), eight follicular lymphoma (FL, 7.7%), seven classical Hodgkin lymphoma (HL, 6.7%), four unspecified peripheral T-cell lymphoma (PTCL, 3.8%), three Burkitt lymphoma (BL, 2.9%), two subcutaneous panniculitis-like T-cell lymphoma (SPTCL, 1.9%), and seven other uncommon types (1% each).
  • Pitfalls in diagnosis of MALT lymphoma, mixed cellularity HL, BL, unspecified PTCL, and FL were 60%, 50%, 33%, 29%, and 24%, respectively.
  • However, considering hematopathologist and non-hematopathologist groups, pitfalls in the former were lower, especially in the uncommon types of lymphoma.
  • [MeSH-major] Diagnostic Errors. Immunophenotyping / standards. Lymphoma / classification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624207.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  •  go-up   go-down






Advertisement